<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Cell Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Cell Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Cell. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Cellular Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1662-5102</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28790893</article-id>
<article-id pub-id-type="pmc">5522882</article-id>
<article-id pub-id-type="doi">10.3389/fncel.2017.00216</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kempuraj</surname>
<given-names>Duraisamy</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/391552/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Thangavel</surname>
<given-names>Ramasamy</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Selvakumar</surname>
<given-names>Govindhasamy P.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zaheer</surname>
<given-names>Smita</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ahmed</surname>
<given-names>Mohammad E.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Raikwar</surname>
<given-names>Sudhanshu P.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zahoor</surname>
<given-names>Haris</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Saeed</surname>
<given-names>Daniyal</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Natteru</surname>
<given-names>Prashant A.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Iyer</surname>
<given-names>Shankar</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zaheer</surname>
<given-names>Asgar</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/414713/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Harry S. Truman Memorial Veteran’s Hospital, U.S. Department of Veterans Affairs</institution>
<country>Columbia, MO, United States</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Neurology and the Center for Translational Neuroscience, School of Medicine, University of Missouri</institution>
<country>Columbia, MO, United States</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Shawn Hayley, Carleton University, Canada</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Giamal Luheshi, McGill University, Canada; Björn Spittau, Albert Ludwig University of Freiburg, Germany</p>
</fn>
<corresp id="fn001">*Correspondence: Duraisamy Kempuraj <email xlink:type="simple">duraisamyk@health.missouri.edu</email> Asgar Zaheer <email xlink:type="simple">zaheera@health.missouri.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>11</volume>
<elocation-id>216</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>4</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 Kempuraj, Thangavel, Selvakumar, Zaheer, Ahmed, Raikwar, Zahoor, Saeed, Natteru, Iyer and Zaheer.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Kempuraj, Thangavel, Selvakumar, Zaheer, Ahmed, Raikwar, Zahoor, Saeed, Natteru, Iyer and Zaheer</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Neuroinflammatory response is primarily a protective mechanism in the brain. However, excessive and chronic inflammatory responses can lead to deleterious effects involving immune cells, brain cells and signaling molecules. Neuroinflammation induces and accelerates pathogenesis of Parkinson’s disease (PD), Alzheimer’s disease (AD) and Multiple sclerosis (MS). Neuroinflammatory pathways are indicated as novel therapeutic targets for these diseases. Mast cells are immune cells of hematopoietic origin that regulate inflammation and upon activation release many proinflammatory mediators in systemic and central nervous system (CNS) inflammatory conditions. In addition, inflammatory mediators released from activated glial cells induce neurodegeneration in the brain. Systemic inflammation-derived proinflammatory cytokines/chemokines and other factors cause a breach in the blood brain-barrier (BBB) thereby allowing for the entry of immune/inflammatory cells including mast cell progenitors, mast cells and proinflammatory cytokines and chemokines into the brain. These peripheral-derived factors and intrinsically generated cytokines/chemokines, α-synuclein, corticotropin-releasing hormone (CRH), substance P (SP), beta amyloid 1–42 (Aβ1–42) peptide and amyloid precursor proteins can activate glial cells, T-cells and mast cells in the brain can induce additional release of inflammatory and neurotoxic molecules contributing to chronic neuroinflammation and neuronal death. The glia maturation factor (GMF), a proinflammatory protein discovered in our laboratory released from glia, activates mast cells to release inflammatory cytokines and chemokines. Chronic increase in the proinflammatory mediators induces neurotoxic Aβ and plaque formation in AD brains and neurodegeneration in PD brains. Glial cells, mast cells and T-cells can reactivate each other in neuroinflammatory conditions in the brain and augment neuroinflammation. Further, inflammatory mediators from the brain can also enter into the peripheral system through defective BBB, recruit immune cells into the brain, and exacerbate neuroinflammation. We suggest that mast cell-associated inflammatory mediators from systemic inflammation and brain could augment neuroinflammation and neurodegeneration in the brain. This review article addresses the role of some atypical inflammatory mediators that are associated with mast cell inflammation and their activation of glial cells to induce neurodegeneration.</p>
</abstract>
<kwd-group>
<kwd>brain</kwd>
<kwd>cytokines and chemokines</kwd>
<kwd>mast cells</kwd>
<kwd>inflammatory mediators</kwd>
<kwd>neuroinflammation</kwd>
<kwd>neurodegenerative diseases</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">U.S. Department of Veterans Affairs<named-content content-type="fundref-id">10.13039/100000738</named-content></funding-source>
<award-id rid="cn001">I01BX002477</award-id>
</award-group>
<award-group>
<funding-source id="cn002">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source>
<award-id rid="cn002">AG048205, NS073670</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="218"></ref-count>
<page-count count="16"></page-count>
<word-count count="14129"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="introduction">
<title>Introduction</title>
<p>Neuroinflammation is an inherent host-defense mechanism to protect and restore the normal structure and function of the brain against infection and injury (More et al., <xref ref-type="bibr" rid="B118">2013</xref>). In neurodegenerative diseases, neuroinflammation initially clears up infection to control the disease severity and progression. However, neuroinflammation also acts as a double-edged sword (Kielian, <xref ref-type="bibr" rid="B88">2016</xref>). On the one side, neuroinflammation induces and/or aggravates neurodegeneration in the central nervous system (CNS), while on the other side, it favors the recovery of the injured neurons (Lucas et al., <xref ref-type="bibr" rid="B110">2006</xref>). A recent study indicates that neuroinflammation promotes regeneration to some extent (Bollaerts et al., <xref ref-type="bibr" rid="B20">2017</xref>). Chronic inflammation induces cytotoxic effects and increases the severity of neurodegenerative disease symptoms. Neuroinflammation is the leading cause of devastating neurodegenerative diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD), Amyotrophic lateral sclerosis (ALS) and Multiple sclerosis (MS)/Experimental autoimmune encephalomyelitis (Chen et al., <xref ref-type="bibr" rid="B27">2016</xref>; Kempuraj et al., <xref ref-type="bibr" rid="B84">2016b</xref>). The activated glial cells release several pro-inflammatory cytokines, chemokines and reactive oxygen species (ROS), which mediate neuroinflammation-induced neurodegenerative disease mechanisms (Kempuraj et al., <xref ref-type="bibr" rid="B84">2016b</xref>). Anti-inflammatory cytokines synthesized by regulatory T cells and neuropeptides secreted by neurons and other cells protect the neurons against neuroinflammation, which helps alleviate the symptoms of neurodegenerative diseases. Recent evidence supports that neuroinflammatory processes involving immune cells, glial cells and neuronal cells are very crucial and fundamental to understanding the origin or pathogenesis of a disease, such as a progressive loss of dopaminergic neurons in PD (Chung et al., <xref ref-type="bibr" rid="B29">2010</xref>; More et al., <xref ref-type="bibr" rid="B118">2013</xref>; Kong et al., <xref ref-type="bibr" rid="B90">2017</xref>; Visan, <xref ref-type="bibr" rid="B201">2017</xref>). Additionally, peripheral inflammation also increases brain inflammatory responses through several mechanisms (Machado et al., <xref ref-type="bibr" rid="B111">2011</xref>; Hernández-Romero et al., <xref ref-type="bibr" rid="B60">2012</xref>; Takeda et al., <xref ref-type="bibr" rid="B179">2013</xref>). Previous studies have shown that non-steroidal anti-inflammatory drugs (NSAIDs), statins and other drugs provide some relief although they are ineffective for neurodegenerative diseases (Szekely and Zandi, <xref ref-type="bibr" rid="B176">2010</xref>; Lehrer, <xref ref-type="bibr" rid="B100">2014</xref>; Kure et al., <xref ref-type="bibr" rid="B95">2017</xref>). This is because the NSAIDs do not efficiently cross the blood brain-barrier (BBB) and do not attain therapeutic levels that are necessary to overcome and reverse neuroinflammation. Therefore, therapeutic options like nasal NSAIDs have been suggested to improve its bioavailability and effectiveness in neuroinflammation by increasing the concentration in the brain (Lehrer, <xref ref-type="bibr" rid="B100">2014</xref>).</p>
<p>The existence of bidirectional communication between the brain and the peripheral immune system has been known over the past two decades (Johnson et al., <xref ref-type="bibr" rid="B73">1997</xref>; Dantzer et al., <xref ref-type="bibr" rid="B34">2000</xref>; Holmes and Butchart, <xref ref-type="bibr" rid="B63">2011</xref>; Hernández-Romero et al., <xref ref-type="bibr" rid="B60">2012</xref>; McCusker and Kelley, <xref ref-type="bibr" rid="B113">2013</xref>; Träger and Tabrizi, <xref ref-type="bibr" rid="B196">2013</xref>; Engelhardt et al., <xref ref-type="bibr" rid="B42">2017</xref>). Neuroinflammation is known to directly and systemically contribute to the recruitment of peripheral inflammatory cells and increase BBB permeability in the neurodegenerative diseases (Hayley and Anisman, <xref ref-type="bibr" rid="B57">2005</xref>; Ferrari and Tarelli, <xref ref-type="bibr" rid="B47">2011</xref>; Espinosa-Oliva et al., <xref ref-type="bibr" rid="B44">2014</xref>; Dendrou et al., <xref ref-type="bibr" rid="B38">2016</xref>; McManus and Heneka, <xref ref-type="bibr" rid="B115">2017</xref>; Schain and Kreisl, <xref ref-type="bibr" rid="B154">2017</xref>). Peripheral infection and inflammation increases BBB permeability and neuroinflammation in the animal model of AD (Takeda et al., <xref ref-type="bibr" rid="B179">2013</xref>). Systemic inflammation also affects hippocampus-dependent memory (Culley et al., <xref ref-type="bibr" rid="B32">2014</xref>; Takeda et al., <xref ref-type="bibr" rid="B178">2014</xref>). Microglia, the macrophage of the brain, is an important resident innate immune cell in the brain. Activation of microglia induces their proliferation in neuroinflammatory conditions (Perry et al., <xref ref-type="bibr" rid="B138">2010</xref>; Perry, <xref ref-type="bibr" rid="B136">2016</xref>). Additionally, astrocytes, neurons, brain pericytes, T cells and mast cells also play a significant role in the brain inflammatory mechanisms. Inflammatory mediators, neurotoxic mediators, inflammasomes and hormones released by the activated glial cells and injured neurons are involved in neuroinflammation in AD and PD pathogenesis (Tufekci et al., <xref ref-type="bibr" rid="B197">2012</xref>; Pennisi et al., <xref ref-type="bibr" rid="B133">2016</xref>; Becher et al., <xref ref-type="bibr" rid="B15">2017</xref>; Gualtierotti et al., <xref ref-type="bibr" rid="B54">2017</xref>; Rustenhoven et al., <xref ref-type="bibr" rid="B147">2017</xref>; Sawikr et al., <xref ref-type="bibr" rid="B152">2017</xref>; Song et al., <xref ref-type="bibr" rid="B172">2017</xref>). Substantia nigra has the highest density of microglial cells, which are found, to be activated in PD brains. In AD, activated microglial cells are found surrounding the beta-amyloid (Aβ) plaques. Microglial activation and inhibition of microglial activation is tightly regulated by a number of microRNAs including pro-inflammatory mir-155 and mir-204 as well as anti-inflammatory mir-203, mir-181c and mir-424 (Cardoso et al., <xref ref-type="bibr" rid="B25">2012</xref>; Li L. et al., <xref ref-type="bibr" rid="B103">2015</xref>). More recently, using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse PD model, a study has shown that 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>) downregulates mir-7116-5p in microglia and potentiates TNF-α production and inflammatory responses leading to DA neuron damage (He et al., <xref ref-type="bibr" rid="B59">2017</xref>).</p>
<p>In addition to significant brain innate immune system activation, peripheral innate immune system activation is recognized as a prominent feature contributing to the severity of neuroinflammatory diseases progression (Träger and Tabrizi, <xref ref-type="bibr" rid="B196">2013</xref>). Systemic inflammation exacerbates clinical symptoms, neuroinflammation and neuronal death in older people and in patients who have suffered stroke and chronic neurodegenerative disease (Teeling and Perry, <xref ref-type="bibr" rid="B182">2009</xref>). Systemic infection and increased IL-1β have been reported to induce a cognitive decline in AD patients (Holmes et al., <xref ref-type="bibr" rid="B65">2003</xref>). Systemic inflammation could induce behavioral and cognitive changes and accelerate neurodegenerative disease pathogenesis (Perry, <xref ref-type="bibr" rid="B134">2004</xref>; Perry et al., <xref ref-type="bibr" rid="B137">2007</xref>; Cunningham et al., <xref ref-type="bibr" rid="B33">2009</xref>). Excess accumulation of activated immune cells in the brain has been well documented in studies covering multiple neurodegenerative diseases. Inflammatory mediator levels in the plasma are elevated in neuroinflammatory conditions. Thus, cytokine levels can be used as a biomarker for neuroinflammatory diseases including PD (Litteljohn and Hayley, <xref ref-type="bibr" rid="B108">2012</xref>). Cytokine and chemokine levels correlate between cerebrospinal fluid (CSF) and plasma in AD (Sun et al., <xref ref-type="bibr" rid="B175">2003</xref>) and PD (Blum-Degen et al., <xref ref-type="bibr" rid="B19">1995</xref>). This indicates that similar type of immune responses occur in the brain and periphery, and show the communication between the brain and peripheral immune systems. An interesting study demonstrated upregulation of nuclear factor-kappaB (NF-κB) activation in the peripheral blood mononuclear cells in AD patients thereby suggesting NF-κB inhibitors as therapeutic agents in AD patients (Ascolani et al., <xref ref-type="bibr" rid="B12">2012</xref>). Imbalance of peripheral T cell subsets (decreased CD8<sup>+</sup> and increased CD4<sup>+</sup> cells) has been reported in AD patients indicating peripheral immune response in AD (Shalit et al., <xref ref-type="bibr" rid="B160">1995</xref>); this is similar to a previous report on brain tumor patients that showed altered peripheral immune parameters in patients with a brain tumor (Kempuraj et al., <xref ref-type="bibr" rid="B80">2004a</xref>). Increased TNF-α levels due to either acute or chronic systemic inflammation have been shown to increase cognitive decline in AD (Holmes et al., <xref ref-type="bibr" rid="B64">2009</xref>) and neurodegeneration in PD (Litteljohn et al., <xref ref-type="bibr" rid="B109">2010</xref>). A previous study has shown that systemic injection of TNF-α into an adult mouse activates brain microglia to produce proinflammatory mediators that induces death of dopaminergic neurons in the substantia nigra (Qin et al., <xref ref-type="bibr" rid="B140">2007</xref>), and this demonstrates a direct link between systemic inflammatory factors and neurodegeneration in the brain. Moreover, during sustained immune response in the brain, several multifunctional pro inflammatory factors, mast cells and T cells from the periphery migrate to the brain, and go directly to or through glial cells while neurons augment and maintain chronic neuroinflammatory responses leading to neurodegeneration (Prinz and Priller, <xref ref-type="bibr" rid="B139">2017</xref>). However, the communication between peripheral inflammatory factors, brain inflammatory factors and the cells in neuroinflammation is not yet clearly understood. Thus, no effective treatment options are currently available for neurodegenerative diseases. Multiple studies have demonstrated that systemic inflammation induces onset and progression of neuroinflammation and neurodegeneration in the CNS. Mast cells play an important role in the systemic inflammation by releasing various inflammatory, neuroactive and vasoactive mediators. Several previous review articles have shown how inflammatory mediators such as IL-1, TNF-α, IL-6, chemokine (C-C motif) ligand 2 (CCL2), ROS released by microglia, T-cells and mast cells induce neuroinflammation. Although mast cells release many neuroinflammatory mediators, we will focus only on select atypical mediators in this review article. This review article will focus on the mast cell associated peripheral and brain inflammatory mediators and mast cells that migrate into the brain and either directly or through astrocytes, microglia and neurons induce and sustain neuroinflammation leading to neuronal death.</p>
</sec>
<sec id="s2">
<title>Mast Cells in Neuroinflammation</title>
<p>Mast cells are crucial in allergic and anaphylactic reactions, acquired and innate immunity, tissue damage and repair processes, and pain mechanisms (Schwartz, <xref ref-type="bibr" rid="B155">2002</xref>; Metz et al., <xref ref-type="bibr" rid="B117">2007</xref>; Galli et al., <xref ref-type="bibr" rid="B49">2008</xref>; Gilfillan et al., <xref ref-type="bibr" rid="B51">2011</xref>; Tete et al., <xref ref-type="bibr" rid="B183">2012</xref>; Saito, <xref ref-type="bibr" rid="B150">2014</xref>; Morita et al., <xref ref-type="bibr" rid="B120">2016</xref>). Mast cells develop from hematopoietic progenitor cells in the bone marrow, move to various tissues and mature into different types of mast cells (Gurish and Austen, <xref ref-type="bibr" rid="B55">2001</xref>). Mast cells are implicated in several allergic and inflammatory diseases including neurodegenerative and demyelinating diseases (Brown and Hatfield, <xref ref-type="bibr" rid="B23">2012</xref>; Conti and Kempuraj, <xref ref-type="bibr" rid="B31">2016</xref>; Russi et al., <xref ref-type="bibr" rid="B146">2016</xref>; Theoharides et al., <xref ref-type="bibr" rid="B191">2016</xref>; Li et al., <xref ref-type="bibr" rid="B102">2017</xref>; Yehya and Torbey, <xref ref-type="bibr" rid="B208">2017</xref>). Mast cells are involved in both peripheral inflammatory conditions and diseases including allergies, asthma, cancer, arthritis, psoriasis, interstitial cystitis, rhinitis, MS, PD, stroke, increased BBB permeability, autism, pain, migraines, sleep disorders, intracerebral hemorrhage, stress and inflammation as shown in Figure <xref ref-type="fig" rid="F1">1</xref>. The systemic inflammatory conditions and diseases can exacerbate neuroinflammation through several different pathways. Mast cells are multifunctional sensor and effector cells in nervous, vascular and immune system disorders (Ryan et al., <xref ref-type="bibr" rid="B148">2009</xref>; Silver et al., <xref ref-type="bibr" rid="B163">2010</xref>). In the brain, mast cells are primarily located on the brain side of the BBB, and communicate with neurons, glia and neurovascular components by releasing their mediators and through mast cell receptors (Silver and Curley, <xref ref-type="bibr" rid="B164">2013</xref>; Dong et al., <xref ref-type="bibr" rid="B40">2014</xref>). Mast cells are generally seen near the glial cells in neuroinflammatory conditions, indicating their interactions with brain cells in neuroinflammation. Various factors such as species, sex, age and outside environmental conditions controls the number and the extent of its activation in the brain (Silver and Curley, <xref ref-type="bibr" rid="B164">2013</xref>). Additionally, the number of mast cells also vary based upon staining and other detection techniques used. In a physiological condition, the total number of mast cells present in the CNS is limited. But, mast cells are very powerful cells and even a few mast cells can release sufficient quantity of inflammatory mediators that can affect BBB and activate glia and neurons in the CNS (Silver and Curley, <xref ref-type="bibr" rid="B164">2013</xref>). Mast cells release neurotrophic factors such as nerve growth factor (NGF) and facilitate neurotransmission, neuronal growth and survival in the normal brain (Kritas et al., <xref ref-type="bibr" rid="B92">2014a</xref>). However, increased number of mast cell involvement and their activation is deleterious, since this could increase BBB permeability, activate astrocytes, oligodendrocytes, microglia and T cells in neuroinflammation (Zhang et al., <xref ref-type="bibr" rid="B215">2016</xref>). Mast cells are resident in the CNS (Skaper et al., <xref ref-type="bibr" rid="B170">2014</xref>), and also able to cross BBB into the brain from the peripheral tissue in neuroinflammatory conditions (Skaper et al., <xref ref-type="bibr" rid="B171">2012</xref>) as well as in physiological conditions (Silverman et al., <xref ref-type="bibr" rid="B165">2000</xref>). Mast cells can recruit and activate other inflammatory cells and glial cells in the brain at the site of inflammation and induce vasodilation in neuroinflammation as shown in Figure <xref ref-type="fig" rid="F2">2</xref> (Nelissen et al., <xref ref-type="bibr" rid="B123">2013</xref>; Yehya and Torbey, <xref ref-type="bibr" rid="B208">2017</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Mast cells in inflammatory diseases. Mast cells play a crucial role in the pathogenesis of many inflammatory diseases of various organs. Certain systemic inflammatory conditions could affect and augment neuroinflammation and neurodegeneration. Therefore, targeting mast cells represents a potentially novel approach to developing the next generation of precision guided therapeutic strategies for the treatment of inflammatory diseases. IBD, inflammatory bowel disease; CAD, coronary artery disease; BBB, blood-brain barrier.</p>
</caption>
<graphic xlink:href="fncel-11-00216-g0001"></graphic>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Schematic diagram showing peripheral inflammatory factors and cells on neuroinflammation and neurodegeneration. Peripheral mast cell activation releases proinflammatory and neurotoxic mediators such as histamine, glia maturation factor (GMF), α-synuclein, corticotropin-releasing hormone (CRH), proteases, cytokines and chemokines. These mediators can induce neuroinflammation by inducing BBB breakdown, entering into the brain and activating glia and neurons to secrete various additional inflammatory mediators. Peripheral mast cells and T-cells enter into the brain, proliferate and secrete proinflammatory mediators that activate glia and neurons to secrete more inflammatory mediators, reduce uncoupling protein (UCP) expression, and induce neurodegeneration. Further, glia and mast cells reactivate each other in the brain through co-stimulatory molecules CD40/CD154 or inflammatory mediators such as TNF-α, IL-1β or IL-33. Mast cell tryptase acts on the neurons through PAR2. Mast cells can reactivate by their own mediators in an autocrine and paracrine manner to exacerbate inflammatory mechanisms. α-synuclein or MPP<sup>+</sup> from glia/neuron or extracellular Aβ1–42 can further activate mast cells to release neuroinflammatory mediators in Alzheimer’s disease (AD) or Parkinson’s disease (PD). Additionally several inflammatory mediators from the peripheral system can alter BBB, enter the brain and activate the neuroinflammatory pathways. Inflammatory mediators released from activated microglia and astrocytes can enter into peripheral system through defective BBB; then, they can activate and recruit immune and inflammatory cells towards the inflammatory site in the brain. MC, mast cell; MCP, mast cell progenitor; TC, T-cell; PAR2, protease activated receptor-2.</p>
</caption>
<graphic xlink:href="fncel-11-00216-g0002"></graphic>
</fig>
<p>Mast cells release multifunctional cytokines/chemokines and neuroactive mediators including IL-1β, IL-6, IL-8, IL-18, IL-33, TNF-α, vascular endothelial growth factor (VEGF), corticotropin-releasing hormone (CRH), granulocyte macrophage-colony stimulating factor (GM-CSF), CCL2, dopamine, substance P (SP), histamine, tryptase, prostaglandins (PGD), leukotrienes, ROS, reactive nitrogen species (RNS) and nitric oxide (NO) selectively depending upon the tissue micro environment and the type of stimuli (Mekori and Metcalfe, <xref ref-type="bibr" rid="B116">2000</xref>; Kalesnikoff and Galli, <xref ref-type="bibr" rid="B75">2008</xref>; Sismanopoulos et al., <xref ref-type="bibr" rid="B166">2012</xref>; Theoharides et al., <xref ref-type="bibr" rid="B186">2012</xref>; Kempuraj et al., <xref ref-type="bibr" rid="B81">2013</xref>). Cytokines such as IL-1β and TNF-α in higher concentrations either directly induce neuronal damage or through activating glial cells, and these cytokines are suggested as a drug target in brain injury therapy (Allan and Rothwell, <xref ref-type="bibr" rid="B4">2001</xref>, <xref ref-type="bibr" rid="B5">2003</xref>; Allan et al., <xref ref-type="bibr" rid="B6">2005</xref>; Brough et al., <xref ref-type="bibr" rid="B22">2015</xref>).</p>
<p>We were the first to show that IL-1 can activate mast cells to release inflammatory mediators (Kandere-Grzybowska et al., <xref ref-type="bibr" rid="B76">2003</xref>). Mast cell-derived vasoactive and inflammatory mediators cause vasoconstriction, increased vascular permeability, edema and inflammatory cell recruitment to the site of inflammation. Mast cells are implicated in all stages of inflammation, tissue damage, and tissue repair mechanisms after the inflammatory responses are over in the inflamed tissues (Kim et al., <xref ref-type="bibr" rid="B89">2011</xref>; Skaper et al., <xref ref-type="bibr" rid="B171">2012</xref>, <xref ref-type="bibr" rid="B169">2013</xref>; Zhang et al., <xref ref-type="bibr" rid="B216">2012</xref>). Mast cells are important sensors of cell injury and damage through IL-33 recognition after it is released from the injured cells (Enoksson et al., <xref ref-type="bibr" rid="B43">2011</xref>). Microglia, the resident brain immune cells and mast cells are considered as two important cells that can mediate neuroinflammation in the brain. Moreover, mast cells can respond and release many neuropeptides that are implicated in the process of neuroinflammation (Tore and Tuncel, <xref ref-type="bibr" rid="B194">2009</xref>; Skaper et al., <xref ref-type="bibr" rid="B171">2012</xref>). Mast cells cross-talk with T-cells, astrocytes, oligodendrocytes and microglia during the pathogenesis of chronic neurodegenerative diseases (Skaper and Facci, <xref ref-type="bibr" rid="B168">2012</xref>; Skaper et al., <xref ref-type="bibr" rid="B171">2012</xref>, <xref ref-type="bibr" rid="B170">2014</xref>; Skaper, <xref ref-type="bibr" rid="B167">2016</xref>). Mast cells can communicate with microglia, astrocytes and neurons through CD40L, CD40, toll-like receptor 2 (TLR2), TLR4, protease-activated receptor 2 (PAR2), CXCR4/C-X-C motif chemokine 12 (CXCL12) and C5aR (CD88). Mast cells also influence glia migration and activation associated with inflammatory mediator release (Kim et al., <xref ref-type="bibr" rid="B89">2011</xref>; Skaper et al., <xref ref-type="bibr" rid="B171">2012</xref>, <xref ref-type="bibr" rid="B169">2013</xref>; Zhang et al., <xref ref-type="bibr" rid="B216">2012</xref>).</p>
<p>Mast cells are the major link between neurons and neuroinflammation (Tore and Tuncel, <xref ref-type="bibr" rid="B194">2009</xref>). Furthermore, mast cells and microglia are known to trigger the activation of two different signaling pathways in neuroinflammation (Skaper et al., <xref ref-type="bibr" rid="B171">2012</xref>; Kempuraj et al., <xref ref-type="bibr" rid="B84">2016b</xref>). Mast cells communicate with neurovascular unit components and induce cognitive dysfunction (Li et al., <xref ref-type="bibr" rid="B102">2017</xref>). Our recent report stating that mast cells are activated by the proinflammatory brain protein glia maturation factor (GMF), strengthens the link between mast cells and brain cells in neuroinflammation (Kempuraj et al., <xref ref-type="bibr" rid="B83">2016a</xref>). Astrocytes also express receptors for mast cells histamine in addition to other receptors indicating the interaction between these cells (Hösli et al., <xref ref-type="bibr" rid="B68">1984</xref>). Mast cell degranulation-derived proteases cleave tryptase-activated receptors (PARs) expressed on the neurons in neuroinflammation and neurodegeneration (Saito and Bunnett, <xref ref-type="bibr" rid="B151">2005</xref>). Mast cell granules also contain dopamine that is released upon activation (Freeman et al., <xref ref-type="bibr" rid="B48">2001</xref>). Previous reports demonstrated that mast cell activation induces and promotes the severity of EAE and that mast cell deficient mice show reduced EAE disease severity. Mast cell reconstitutions into mast cell-deficient mice have been used to study the role of mast cells in CNS diseases (Secor et al., <xref ref-type="bibr" rid="B156">2000</xref>; Sayed et al., <xref ref-type="bibr" rid="B153">2011</xref>). Reconstitution of mast cell deficient mice with cultured mouse bone marrow-derived mast cells (BMMCs) generally restores mast cells in the CNS (Johnson et al., <xref ref-type="bibr" rid="B72">1991</xref>). Mast cells could also act outside the CNS to influence its effects inside the CNS as demonstrated in EAE models (Tanzola et al., <xref ref-type="bibr" rid="B180">2003</xref>). Previous study has shown that mast cell reconstitution in mast cell-deficient mice restores conditions similar to wild type mice (Enoksson et al., <xref ref-type="bibr" rid="B43">2011</xref>). Mast cells can communicate with neurons through the cell adhesion molecule-1 (CADM), N-cadherin, and through the transgranulation process (Wilhelm et al., <xref ref-type="bibr" rid="B205">2005</xref>; Héron and Dubayle, <xref ref-type="bibr" rid="B61">2013</xref>). Activated mast cells induce BBB permeability by releasing vasoactive molecules such as histamine, proteases and metalloproteinases (Héron and Dubayle, <xref ref-type="bibr" rid="B61">2013</xref>). Mast cell-derived histamine affects sleep-wakefulness and other basic behavioral functions (Chikahisa et al., <xref ref-type="bibr" rid="B28">2013</xref>). The types and strength of activation signals as well as mast cell phenotype determine the extent of mast cell activation in inflammatory conditions. Mast cell activation leads to acute explosive degranulation (rapid process) with inflammatory mediators released into extracellular spaces, and also by the selective release of cytokines and chemokines (slow process) (Nelissen et al., <xref ref-type="bibr" rid="B123">2013</xref>). Mast cell-derived mediators that could disrupt BBB include CRH, histamine, VEGF, IL-8, TNF-α, tryptase, prostaglandin D2 (PGD<sub>2</sub>), SP, bradykinin, endorphin, endothelin, neurotensin, NO, vasoactive intestinal polypeptide (VIP) and urocortin (Abbott, <xref ref-type="bibr" rid="B1">2000</xref>; Theoharides and Konstantinidou, <xref ref-type="bibr" rid="B187">2007</xref>; Theoharides et al., <xref ref-type="bibr" rid="B190">2008</xref>; Gu et al., <xref ref-type="bibr" rid="B53">2015</xref>).</p>
<p>Aβ1–42 is the major component of amyloid plaques (APs) in an AD brain. Aβ1–42 is known to activate mast cells that could play an important role in AD pathogenesis (Niederhoffer et al., <xref ref-type="bibr" rid="B125">2009</xref>). In fact the presence of Aβ and tau-protein was detected in the mast cells of peripheral organs such as the skin and stomach of patients with AD (Kvetnoi et al., <xref ref-type="bibr" rid="B96">2003</xref>). Dopaminergic neuronal injury may be detected by mast cells since these cells can detect cellular injury through the IL-33 recognition mechanism (Enoksson et al., <xref ref-type="bibr" rid="B43">2011</xref>). We suggest that in addition to the well-known glial cells activation, mast cells activation with subsequent release of proinflammatory cytokines and chemokines from mast cells as well as mast cell-mediated enhanced proinflammatory mediators from the glia could exacerbate neuroinflammatory conditions leading to neurodegeneration in PD and AD. Our recent findings suggest that activation of mast cells by GMF, MPP<sup>+</sup> and α-synuclein and release of cytokines, chemokines and neurotoxic molecules and the expression of GMF by mast cells indicate new drug targets for PD and other neuroinflammatory conditions (Kempuraj et al., <xref ref-type="bibr" rid="B85">2015</xref>, <xref ref-type="bibr" rid="B83">2016a</xref>). This review article mainly deals with mast cell association with mitochondrial uncoupling proteins (UCPs), α-synuclein, GMF, CRH, SP and dopamine in neuroinflammatory conditions.</p>
</sec>
<sec id="s3">
<title>Mitochondrial Uncoupling Protein (UCP) in Neuroinflammation</title>
<p>UCP2 and UCP4, members of the UCP family are neuroprotective by reducing the formation of ROS and are implicated in neurodegeneration and brain injury (Normoyle et al., <xref ref-type="bibr" rid="B127">2015</xref>), AD (Wu et al., <xref ref-type="bibr" rid="B207">2010</xref>) and PD (Andrews et al., <xref ref-type="bibr" rid="B8">2005</xref>; Ho et al., <xref ref-type="bibr" rid="B62">2012</xref>; Peixoto et al., <xref ref-type="bibr" rid="B132">2013</xref>). UCPs reside on the inner mitochondrial membrane where they alter the mitochondrial membrane potential and ROS production and protect neurons (Cardoso et al., <xref ref-type="bibr" rid="B26">2015</xref>). UCP2 and UCP4 regulate intracellular calcium levels and neurotransmission in the neurons. Abnormal expression of UCP2 and UCP4 has been reported in AD (Wu et al., <xref ref-type="bibr" rid="B206">2009</xref>, <xref ref-type="bibr" rid="B207">2010</xref>). Overexpression or activation of UCP2 and UCP4 may be a new strategy for reducing allergic and inflammatory responses since overexpression protects neurons after MPP<sup>+</sup> and dopamine-induced toxicity (Ho et al., <xref ref-type="bibr" rid="B62">2012</xref>). UCP4 is primarily expressed in the brain (Ramsden et al., <xref ref-type="bibr" rid="B141">2012</xref>). UCP4 is neuroprotective and important in energy homeostasis and is decreased in PD mice model. Overexpression of UCP4 reduced oxidative stress and inhibited apoptosis (Ho et al., <xref ref-type="bibr" rid="B62">2012</xref>; Ramsden et al., <xref ref-type="bibr" rid="B141">2012</xref>). The expression of UCP2 was demonstrated in lymphocytes, dendritic cells, neutrophils and macrophages (Rousset et al., <xref ref-type="bibr" rid="B145">2006</xref>). UCP2<sup>−/−</sup> mice develop more severe EAE (Aheng et al., <xref ref-type="bibr" rid="B3">2011</xref>). Macrophages from UCP2<sup>−/−</sup> mice have a greater inflammatory response to lipopolysaccharide (LPS), including increased NF-κB activation and greater cytokine production. Macrophages overexpressing UCP2 produce less ROS in response to LPS (Negre-Salvayre et al., <xref ref-type="bibr" rid="B122">1997</xref>) and have decreased transendothelial migration (Ryu et al., <xref ref-type="bibr" rid="B149">2004</xref>). Both mitochondrial and cytosolic ROS are also produced by mast cells. Inhibition of ROS production reduces mast cell degranulation, indicating that ROS may play a role in regulating exocytosis process.</p>
<p>Recent studies have suggested that UCP2 manipulation could drive microglia towards protective phenotypes (De Simone et al., <xref ref-type="bibr" rid="B36">2015</xref>). UCP2 activity inhibits exocytosis of dopamine-containing vesicles from rat PC12 cells. UCP2 also dampens the inflammatory response of macrophages. We have previously reported the expression of UCP2 by mouse mast cells, and the LAD 2 human mast cell line, and recently showed the expression of UCP4 by mouse mast cells using immunohistochemical staining (Tagen et al., <xref ref-type="bibr" rid="B177">2009</xref>; Kempuraj et al., <xref ref-type="bibr" rid="B83">2016a</xref>). UCP<sup>−/−</sup> mouse BMMCs have greater release of proinflammatory molecules after both allergic and non-allergic triggers, in addition to having increased histamine content and increased skin vascular permeability (Tagen et al., <xref ref-type="bibr" rid="B177">2009</xref>). Activated BMMCs from UCP2<sup>−/−</sup> mice have exhibited greater histamine release, whereas overexpression of UCP2 in LAD2 mast cells have reduced histamine release. UCP2<sup>−/−</sup> BMMCs have also had elevated histamine content and histidine decarboxylase expression (Tagen et al., <xref ref-type="bibr" rid="B177">2009</xref>). UCP2<sup>−/−</sup> BMMCs have also had greater production of both IL-6 and PGD<sub>2</sub>, as well as extracellular signal-regulated kinase (ERK) phosphorylation, which is known to regulate prostaglandin synthesis (Tagen et al., <xref ref-type="bibr" rid="B177">2009</xref>). UCP2 can regulate mast cell activation in neuroinflammatory conditions. These studies indicate that UCP2 is a novel regulator of mast cell function with a potential for treatment of mast cell-mediated allergic and inflammatory diseases including neurodegenerative and autoimmune diseases (Tagen et al., <xref ref-type="bibr" rid="B177">2009</xref>; Ho et al., <xref ref-type="bibr" rid="B62">2012</xref>). We have recently shown a downregulation of expression of both UCP2 and UCP4 in the parahippocampal gyrus of AD brains (Thangavel et al., <xref ref-type="bibr" rid="B184">2017</xref>). All these reports show that UCPs expression dynamics in mast cells in the peripheral tissue as well as in the CNS could influence the neuroprotective state. Therefore, it would be worthwhile to examine the molecular mechanism/s underlying transcriptional and posttranscriptional regulation of UCP2 and UCP4. Especially, it would be interesting to decipher the potential role of microRNAs in downregulating the expression of UCP2 and UCP4, not only in AD, but also in PD and other neurodegenerative diseases. Furthermore, targeted overexpression of UCP2 and UCP4 in neurodegenerative diseases could potentially establish their therapeutic as well as neuroprotective effects.</p>
</sec>
<sec id="s4">
<title>α-Synuclein in Neuroinflammation</title>
<p>α-synuclein is a cytosolic protein expressed in many immune cells and forms Lewy bodies in the PD brain. α-synuclein is the major component in Lewy bodies and it has been identified as a possible biomarker for PD (Si et al., <xref ref-type="bibr" rid="B162">2017</xref>). α-synuclein is produced by cells in the peripheral tissues as well as from the CNS cells; it is also reported in the blood along with CSF (Sui et al., <xref ref-type="bibr" rid="B174">2014</xref>). α-synuclein is present in the neurons and glia of substantia nigra, thalamus, neocortex and hippocampus. α-synuclein is implicated in both physiological and pathological functions. This cytosolic protein plays an important role in the pathogenesis of PD by inducing neuronal death in the substantia nigra. Extracellular α-synuclein can induce neuroinflammatory reactions in glial cells leading to neurodegeneration. Radiolabeled α-synuclein has been demonstrated to move across BBB in both directions and this movement could have important therapeutic significance (Sui et al., <xref ref-type="bibr" rid="B174">2014</xref>). High levels of α-synuclein in blood could contribute to CNS pathology, since the plasma levels of α-synuclein are significantly higher than in the CSF levels (Shi et al., <xref ref-type="bibr" rid="B161">2014</xref>). α-synuclein from neurons enter into the glial cells and induce the secretion of proinflammatory cytokines and chemokines; moreover, this release is directly proportional to the amount of α-synuclein in the glial cells (Lee et al., <xref ref-type="bibr" rid="B98">2010</xref>). Recently, a neuron-to-neuron transfer of α-synuclein aggregates has been reported in the cell culture system as well as in transgenic mice with neuronal progenitor cell grafts (Desplats et al., <xref ref-type="bibr" rid="B39">2009</xref>). The transferred α-synuclein induces Lewy bodies-like inclusion and apoptotic changes in the recipient neurons. Thus, neuronal-derived excess α-synuclein is transferred and accumulates in the neurons and glia, inducing pathological inclusion formation and degenerative changes. An increased level of α-synuclein can directly bind and disrupt mitochondria (Mullin and Schapira, <xref ref-type="bibr" rid="B121">2013</xref>). α-synuclein in other non-CNS immune cells in the peripheral systems could play an important role in the pathogenesis of PD and other synucleinopathies.</p>
<p>The levels of α-synuclein and phagocytosis may be useful biomarkers in PD patients. PD involves α-synuclein pathology and tissue dysfunction in multiple organs. α-synuclein levels were elevated in monocytes and lymphocytes of sporadic PD patients when compared to control subjects. Increased α-synuclein staining was confirmed by immunoblot analysis of a subset of the peripheral blood mononuclear cells. Elevated α-synuclein is not limited to familial PD, but is also observed in sporadic PD. However, reports regarding the expression of α-synuclein in microglial cells and macrophages are conflicting. In an interesting study, Zhou et al. (<xref ref-type="bibr" rid="B217">2016</xref>) have utilized the MPTP mouse model of PD to decipher the role of α-synuclein and mir-7 on the activation of NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome and neuroinflammation. These studies suggest that mir-7 targets NLRP3 expression besides α-synuclein and modulates NLRP3 inflammasome mediated inflammation. Increased α-synuclein expression with age has been reported in macrophages; however, other studies have reported no expression at all. Previous studies have shown that misfolded α-synuclein directly activates microglia inducing the production and release of the proinflammatory cytokines while increasing antioxidant enzyme expression. In the nigrostriatal system, dopamine is a prominent source of ROS. Therefore, the nigrostriatal system may exhibit enhanced vulnerability and be more prone to PD because this region has high levels of oxidative stress and is enriched in α-synuclein as well as dopamine. α-synuclein is the major component of Lewy bodies responsible for Lewy neuritis in sporadic PD, dementia with Lewy Bodies and a Lewy Body variant of AD. Further, α-synuclein is implicated in glia activation, oxidative stress, neuronal dysfunction, neuroinflammation and neurodegeneration (Béraud et al., <xref ref-type="bibr" rid="B16">2013</xref>). We have previously shown that α-synuclein induced chemokine IL-8 release from cultured human mast cells <italic>in vitro</italic> (Kempuraj et al., <xref ref-type="bibr" rid="B85">2015</xref>) indicating that α-synuclein released in the brain could activate mast cells in inflammatory conditions <italic>in vivo</italic>. A peripheral source of α-synuclein could influence neuroinflammation and neurodegeneration in the CNS.</p>
</sec>
<sec id="s5">
<title>GMF in Neuroinflammation</title>
<p>GMF is a novel multifunctional, brain-dominant protein first discovered (Lim et al., <xref ref-type="bibr" rid="B106">1989</xref>, <xref ref-type="bibr" rid="B105">1990a</xref>; Kaplan et al., <xref ref-type="bibr" rid="B77">1991</xref>; Zaheer et al., <xref ref-type="bibr" rid="B209">1993</xref>), purified, sequenced, and cloned in our laboratory (Lim et al., <xref ref-type="bibr" rid="B106">1989</xref>, <xref ref-type="bibr" rid="B107">1990b</xref>). GMF is mainly expressed in the glia in the CNS and is an important factor in neuroinflammation and neurodegeneration in the CNS (Zaheer et al., <xref ref-type="bibr" rid="B212">2007</xref>). We have previously reported increased expression of GMF in the CNS of neurodegenerative and autoimmune disorders (Zaheer et al., <xref ref-type="bibr" rid="B214">2011</xref>; Thangavel et al., <xref ref-type="bibr" rid="B185">2012</xref>; Stolmeier et al., <xref ref-type="bibr" rid="B173">2013</xref>; Kempuraj et al., <xref ref-type="bibr" rid="B84">2016b</xref>). More recently we have also shown that upregulation of GMF is associated with downregulation of UCPs in AD brains (Thangavel et al., <xref ref-type="bibr" rid="B184">2017</xref>). Other investigators have previously demonstrated the expression of GMF in the extra CNS cells/tissues such as in macrophages and peripheral organs (Kaimori et al., <xref ref-type="bibr" rid="B74">2003</xref>; Utsuyama et al., <xref ref-type="bibr" rid="B198">2003</xref>). GMF is a proinflammatory mediator released from glial cells (Zaheer et al., <xref ref-type="bibr" rid="B210">2008a</xref>), and GMF-knockout (GMF-KO) mice showed reduced glial activation and significantly suppressed proinflammatory molecules expression after Aβ infusion when compared to wild type mice (Zaheer et al., <xref ref-type="bibr" rid="B213">2008b</xref>). Primary astrocyte and microglia cultures obtained from GMF-KO mice showed a reduced expression of inflammatory cytokines and chemokines compared to glia obtained from wild type cells, and returned to control levels after reconstitution with an adenoviral construct (Zaheer et al., <xref ref-type="bibr" rid="B213">2008b</xref>). GMF activates astrocytes through p38 mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways (Zaheer et al., <xref ref-type="bibr" rid="B211">2001</xref>, <xref ref-type="bibr" rid="B212">2007</xref>). GMF activates both human and mouse mast cells. Further, our previous studies have shown that BMMCs obtained from GMF-KO mice released less CCL2 than BMMCs obtained from wild type mice. We have also shown that lack of GMF in astrocytes increases antioxidant level and reduces the production of ROS in MPP<sup>+</sup>-mediated toxicity (Khan et al., <xref ref-type="bibr" rid="B86">2014</xref>). We have previously shown the expression of GMF in the cultured mouse and human mast cells by immunocytochemistry (Kempuraj et al., <xref ref-type="bibr" rid="B85">2015</xref>). The lack of GMF reduces the release of inflammatory molecules from mast cells. We have shown that GMF, α-synuclein, MPP<sup>+</sup>, and IL-33 significantly increased the release of IL-8 from human mast cells (Kempuraj et al., <xref ref-type="bibr" rid="B85">2015</xref>). Further, we have shown that incubation of human mast cells with IL-33 upregulates the expression of GMF indicating that GMF expression could be increased during mast cell activation in neurodegenerative diseases. Mast cells could release the stored or newly synthesized GMF during the neuroinflammatory conditions along with other proinflammatory molecules in response to MPP<sup>+</sup>, α-synuclein, Aβ or other PD and AD-relevant proinflammatory molecules.</p>
<sec id="s5-1">
<title>GMF Expression in Systemic Pathological Conditions</title>
<p>The expression of GMF could be enhanced in several systemic inflammatory diseases. An earlier study has shown that GMF enhances oxidative stress in renal diseases. GMF is normally absent in the kidney but the expression of GMF is inducible in the proximal renal tubules under the stress of proteinuria and in non-brain tissues (Imai et al., <xref ref-type="bibr" rid="B70">2015</xref>). Thymus shows the expression of GMF, which is important in T cell development (Utsuyama et al., <xref ref-type="bibr" rid="B198">2003</xref>). GMF overexpression in non-brain cells increases the vulnerability to oxidative stress and apoptosis (Kaimori et al., <xref ref-type="bibr" rid="B74">2003</xref>). Another study showed up-regulation of GMF expression in the lesions of 246 human serous ovarian carcinoma (SOC) patients and that high GMF expression exhibited lower disease-free and overall survival rates (Li et al., <xref ref-type="bibr" rid="B104">2010</xref>). Other studies have reported that GMF-γ increased in the cardiac ischemia model with inflammation and angiogenesis (Ikeda et al., <xref ref-type="bibr" rid="B69">2006</xref>). Furthermore, GMF-γ is an important regulator of neutrophil chemotaxis (Aerbajinai et al., <xref ref-type="bibr" rid="B2">2011</xref>). GMF released from systemic inflammation could increase the GMF level in the periphery and this increased GMF may enter into the brain and induce or augment neuroinflammation by activating glia, neurons, mast cells and T-cells. Thus, peripheral-derived GMF may also increase the neuroinflammatory mechanisms in neurodegenerative diseases similar to other inflammatory mediators as shown in Figure <xref ref-type="fig" rid="F2">2</xref>.</p>
</sec>
</sec>
<sec id="s6">
<title>Neuropeptides SP and CRH in Neuroinflammation</title>
<p>SP is a neurotrophic and neuroprotective factor and can directly modulate glial functions in the brain (Severini et al., <xref ref-type="bibr" rid="B158">2016</xref>). SP is an important proinflammatory neuropeptide that can activate glia and induce neurodegeneration in the CNS (Li W. W. et al., <xref ref-type="bibr" rid="B101">2015</xref>). Elevated levels of SP have been reported in the CSF of AD patients when compared with dementias and control subjects. Further, this increase corresponded to the increased level of Aβ1–42 in the CSF of AD patients (Johansson et al., <xref ref-type="bibr" rid="B71">2015</xref>). However, a reduced level of SP was also reported in the brain and CSF of AD patients (Severini et al., <xref ref-type="bibr" rid="B158">2016</xref>). SP concentration in the subsantia nigra is high and this may be responsible for the increased microglia in this region (Wang et al., <xref ref-type="bibr" rid="B203">2015</xref>). Neuropeptides are involved in neurogenic inflammation and many neuropeptides, including SP, induce mast cell activation and release several neuroinflammatory cytokines, chemokines, tryptase and histamine (Nicoletti et al., <xref ref-type="bibr" rid="B124">2012</xref>). SP is the most abundant neuropeptide in the CNS and is distributed in the peripheral tissues. It has been demonstrated that SP enhances human T-cell proliferation responses and causes an increased synthesis of CC and CXC chemokines. In addition, SP and CRH also induce the synthesis and release of cytokines/chemokines such as TNF-α, CCL2, CCL3, CCL5, GM-CSF, CXCL8, proteases tryptase and chymase, histamine, leukotrienes and PGD<sub>2</sub> from mast cells (Katsanos et al., <xref ref-type="bibr" rid="B79">2008</xref>). SP is a mediator of neuroinflammation as well as a key element in striatonigral circuitry. PD patients and animal models of PD show dopaminergic neuronal death in the substantia nigra region of the brain. SP increases dopaminergic neuronal death directly and is also induced by LPS or MPP<sup>+</sup> (Wang et al., <xref ref-type="bibr" rid="B202">2014</xref>). Dopamine induces the release of SP in substantia nigra and the SP potentiate dopamine release in a positive feedback pathway mechanism (Thornton et al., <xref ref-type="bibr" rid="B193">2010</xref>). The substantia nigra has bidirectional neuronal connections with the striatum. Striatal neurons innervate the substantia nigra pars compacta, releasing SP and activating inflammatory cells. We and others have previously shown that several neuropeptides such as SP (Cocchiara et al., <xref ref-type="bibr" rid="B30">1999</xref>; Azzolina et al., <xref ref-type="bibr" rid="B13">2003</xref>; Kulka et al., <xref ref-type="bibr" rid="B94">2008</xref>; Taracanova et al., <xref ref-type="bibr" rid="B181">2017</xref>) and CRH (Theoharides et al., <xref ref-type="bibr" rid="B189">2004</xref>; Alysandratos et al., <xref ref-type="bibr" rid="B7">2012</xref>) are known to activate mast cells to release proinflammatory cytokines and chemokines (Kulka et al., <xref ref-type="bibr" rid="B94">2008</xref>; Shaik-Dasthagirisaheb et al., <xref ref-type="bibr" rid="B159">2013</xref>). Mast cell mediators such as histamine in turn activate microglia and release neuroinflammatory mediators in the brain (Zhu et al., <xref ref-type="bibr" rid="B218">2014</xref>). SP and CRH are important mediators of neuroinflammation and BBB dysfunctions (Esposito et al., <xref ref-type="bibr" rid="B45">2002</xref>; Thornton and Vink, <xref ref-type="bibr" rid="B192">2012</xref>). Increased SP levels have been reported in 6-hydroxydopamine hydrochloride (6-OHDA)-induced PD animal models. A recent report shows that an integrated microfluidic immuno chip can be used as a sensitive, rapid and quantitative detection of SP in the serum of neuroinflammatory conditions (Horak et al., <xref ref-type="bibr" rid="B67">2014</xref>). Previous study has shown that treatment with an SP receptor antagonist is neuroprotective in the intra striatal 6-hydroxydopamine-induced PD (Thornton and Vink, <xref ref-type="bibr" rid="B192">2012</xref>). However, some studies reported decreased SP levels in the substantia nigra of PD (Fernandez et al., <xref ref-type="bibr" rid="B46">1992</xref>). SP can activate glial nicotinamide adenine dinucleotide phosphate (NADPH) oxidase to release ROS (Block et al., <xref ref-type="bibr" rid="B18">2006</xref>).</p>
<p>CRH is the principal coordinator of the stress response by activating the hypothalamo-pituitary-adrenal (HPA) axis (Dedic et al., <xref ref-type="bibr" rid="B37">2017</xref>). CRH is released by neurons in the hypothalamus and in extra CNS cells including mast cells (Kempuraj et al., <xref ref-type="bibr" rid="B82">2004b</xref>; Pardon, <xref ref-type="bibr" rid="B130">2011</xref>). CRH could regulate neuroinflammation by increasing the apoptosis of microglia and activation of mast cells (Ock et al., <xref ref-type="bibr" rid="B128">2006</xref>). CRH can activate microglia through CRH R and release inflammatory mediators (Kritas et al., <xref ref-type="bibr" rid="B93">2014b</xref>). Moreover, SP is known to induce the expression of CRH in glia (Hamke et al., <xref ref-type="bibr" rid="B56">2006</xref>). Emotional/chronic stress enhance glial activation and exacerbates neuronal death through inflammation in the substantia nigra of the PD brain (De Pablos et al., <xref ref-type="bibr" rid="B35">2014</xref>). A case report suggested that major stress could have triggered PD in a young woman (Zou et al., <xref ref-type="bibr" rid="B219">2013</xref>). Stress-induced striatal damage, with subsequent worsening of motor symptoms has been reported in animal models of PD. CRH is also implicated in AD pathogenesis including the generation of Aβ (Pardon, <xref ref-type="bibr" rid="B130">2011</xref>; Marcello et al., <xref ref-type="bibr" rid="B112">2015</xref>). CRH could stimulate mast cells and glial activation and their proliferations in neuroinflammation (Theoharides et al., <xref ref-type="bibr" rid="B188">2013</xref>). We have shown the expression of CRH as well as CRH R in mast cells (Kempuraj et al., <xref ref-type="bibr" rid="B82">2004b</xref>; Cao et al., <xref ref-type="bibr" rid="B24">2005</xref>; Papadopoulou et al., <xref ref-type="bibr" rid="B129">2005</xref>). CRH released from activated mast cells could also activate glial cells in neurodegenerative conditions (Kempuraj et al., <xref ref-type="bibr" rid="B82">2004b</xref>). SP also induces CRH receptor expression on mast cells (Asadi et al., <xref ref-type="bibr" rid="B11">2012</xref>). In fact, administration of inflammatory cytokines induces a depressive disorder similar to the one induced by stressors (Anisman et al., <xref ref-type="bibr" rid="B10">2002</xref>; Gibb et al., <xref ref-type="bibr" rid="B50">2009</xref>; Anisman and Hayley, <xref ref-type="bibr" rid="B9">2012</xref>; Hayley et al., <xref ref-type="bibr" rid="B58">2013</xref>). Thus, stressful conditions can activate peripheral mast cells; activate CRH and SP pathways leading to increased BBB permeability, increased glial activation and more severe neuroinflammation and neurodegenerative diseases.</p>
</sec>
<sec id="s7">
<title>Dopamine in Neuroinflammation</title>
<p>Neurotransmitter dopamine is implicated in the pathogenesis of PD and in AD (Bisaglia et al., <xref ref-type="bibr" rid="B17">2014</xref>; Nobili et al., <xref ref-type="bibr" rid="B126">2017</xref>). Self-oxidation of dopamine to dopamine quinone, aminochrome and 5,6-indolequinone mediate PD pathogenesis since aminochrome induces mitochondrial dysfunctions (Segura-Aguilar et al., <xref ref-type="bibr" rid="B157">2014</xref>). The dying neurons in PD release neuromelanin, which induces glial cells activation, and augments neuroinflammatory reactions. Substantia nigra dopamine levels are implicated in 6-OHDA induced recruitment of peripheral inflammatory cells into the nigrostriatal regions in the brain (Espinosa-Oliva et al., <xref ref-type="bibr" rid="B44">2014</xref>). Dopamine can activate microglia to release inflammatory mediators and increase oxidative stress as they express receptors for dopamine (Labandeira-Garcia et al., <xref ref-type="bibr" rid="B97">2013</xref>; Lee, <xref ref-type="bibr" rid="B99">2013</xref>). Mast cells also can synthesize and store dopamine in secretory granules and tyrosine hydroxylase, a key precursor enzyme in dopamine biosynthesis (Freeman et al., <xref ref-type="bibr" rid="B48">2001</xref>; Ronnberg et al., <xref ref-type="bibr" rid="B144">2012</xref>). The amount of dopamine synthesis and storage increases along with mast cell maturation (Ronnberg et al., <xref ref-type="bibr" rid="B144">2012</xref>). Mast cells express D1-like dopamine receptors (Mori et al., <xref ref-type="bibr" rid="B119">2013</xref>) and vesicular monoamine transporters (VMAT2). The D1-like dopamine receptor and VMAT2 transport dopamine/MPP<sup>+</sup> in mast cells could induce the generation of ROS and the release of inflammatory mediators. D1-like receptors play an important role in allergic reactions in the skin through the T-helper (Th2) formation and mast cell activation (Mori et al., <xref ref-type="bibr" rid="B119">2013</xref>). The expression of tyrosine hydroxylase is induced during mast cell maturation (Ronnberg et al., <xref ref-type="bibr" rid="B144">2012</xref>). Mast cell activation can release dopamine along with other inflammatory mediators (Freeman et al., <xref ref-type="bibr" rid="B48">2001</xref>) and augment neuroinflammation. Dopamine influences mast cell interaction with T cells. Thus, peripheral as well as brain mast cell activation can influence neuroinflammatory mechanisms.</p>
</sec>
<sec id="s8">
<title>Mechanisms by Which Peripheral Inflammatory Factors and Inflammatory Cells Augment Neuroinflammation</title>
<p>AD patients show abnormalities in peripheral tissues, immune and inflammatory cells in addition to the pathological changes observed in the brain regions (Khan and Alkon, <xref ref-type="bibr" rid="B87">2014</xref>). Drugs targeting neuroinflammation represent next generation of therapeutic agents for treating AD and PD (Bronzuoli et al., <xref ref-type="bibr" rid="B21">2016</xref>; McKenzie et al., <xref ref-type="bibr" rid="B114">2017</xref>). Studies have shown that peripheral inflammation exacerbates neuroinflammation and neurodegeneration in the brain including its substantia nigra region (Perry, <xref ref-type="bibr" rid="B135">2010</xref>; Villarán et al., <xref ref-type="bibr" rid="B200">2010</xref>; Machado et al., <xref ref-type="bibr" rid="B111">2011</xref>; Hernández-Romero et al., <xref ref-type="bibr" rid="B60">2012</xref>; Träger and Tabrizi, <xref ref-type="bibr" rid="B196">2013</xref>). Animal studies have shown systemic inflammation activates microglia in the brain and releases inflammatory mediators (Hoogland et al., <xref ref-type="bibr" rid="B66">2015</xref>). High levels of IL-6, TNF-α and CCL2 in the plasma and serum of AD, PD and MS patients as well as in various systemic inflammatory diseases can induce the neurodegenerative pathways in these diseases (Träger and Tabrizi, <xref ref-type="bibr" rid="B196">2013</xref>). Systemic inflammation also increases BBB permeability in AD (Takeda et al., <xref ref-type="bibr" rid="B179">2013</xref>). Normally BBB, formed by endothelial cells and astrocyte end-feet, restricts transfer of larger molecules and cells into the brain. Cytokines/chemokines and other proinflammatory molecules have been shown to cross BBB by an active transport mechanism (Banks et al., <xref ref-type="bibr" rid="B14">1995</xref>) or through circumventricular organs that lack BBB (Perry et al., <xref ref-type="bibr" rid="B137">2007</xref>). The peripheral immune and inflammatory mediators can interact with brain BBB endothelial cells and induce the release of additional inflammatory molecules including PGD<sub>2</sub> into the brain (Ek et al., <xref ref-type="bibr" rid="B41">2001</xref>). Systemic immune cells such as T cells can infiltrate into the brain through the BBB via choroid plexus or CSF that could induce neurodegeneration (Ransohoff et al., <xref ref-type="bibr" rid="B143">2003</xref>; Park et al., <xref ref-type="bibr" rid="B131">2016</xref>). Peripheral inflammation is also translated to the brain through the vagus nerve by neural reflex (Tracey, <xref ref-type="bibr" rid="B195">2009</xref>). As the BBB is disrupted in neurodegenerative diseases, the flow of immune cells and inflammatory molecules across the BBB is increased and thereby increases neuroinflammation (Kortekaas et al., <xref ref-type="bibr" rid="B91">2005</xref>; Takeda et al., <xref ref-type="bibr" rid="B179">2013</xref>). Several previous reports indicate that mast cell activation (Karagkouni et al., <xref ref-type="bibr" rid="B78">2013</xref>; Zhang et al., <xref ref-type="bibr" rid="B215">2016</xref>), as well as peripheral inflammation influences BBB disruption to increase the permeability of inflammatory mediators and immune cell infiltration into the brain thereby spreading peripheral inflammation into the brain (Takeda et al., <xref ref-type="bibr" rid="B179">2013</xref>). Peripheral inflammation due to LPS injection increases neuroinflammation without increasing Aβ level in the AD mouse model, indicating neuroinflammation could increase without increasing the Aβ level in the brain (Takeda et al., <xref ref-type="bibr" rid="B179">2013</xref>). A recent article reported that immunotherapy which induces Aβ clearance alone does not improve cognitive improvement in AD patients and indicates the contribution of systemic inflammation in these patients (Goldeck et al., <xref ref-type="bibr" rid="B52">2016</xref>). Activated microglia and astrocytes release inflammatory mediators, which enter the peripheral system through the defective BBB and recruit immune cells to the brain, thereby exacerbating neuroinflammatory mechanisms (Goldeck et al., <xref ref-type="bibr" rid="B52">2016</xref>).</p>
<p>The brain was originally considered as an immunologically privileged organ but now it is well known that the peripheral immune system and the brain communicate through several pathways (Ransohoff and Brown, <xref ref-type="bibr" rid="B142">2012</xref>). We have previously shown that the presence of a tumor in the brain affects peripheral blood immune parameters (Kempuraj et al., <xref ref-type="bibr" rid="B80">2004a</xref>). Several peripheral inflammatory conditions (Figure <xref ref-type="fig" rid="F1">1</xref>) could activate mast cells and release proinflammatory and neurotoxic mediators such as GMF, α-synuclein, CRH, neurotensin, proteases, cytokines and chemokines. These mediators can cause up-regulation of the neuroinflammatory mechanisms (Träger and Tabrizi, <xref ref-type="bibr" rid="B196">2013</xref>) by the following mechanisms. These mediators can induce BBB breakdown, enter into the brain and activate glia and neurons to release various neuroinflammatory mediators. Further peripheral mast cells, mast cell progenitor cells and T-cells enter into the brain, proliferate, mature and secrete additional inflammatory mediators. Inflammatory mediators released from these cells activate glia and neurons to secrete additional inflammatory mediators including GMF and neuropeptides reduce UCP expression, and induce neuronal damage and neurodegeneration. Further, glia and mast cells reactivate each other in the brain through co-stimulatory molecules CD40/CD154 or inflammatory mediators such as TNF-α, IL-1β or IL-33. Mast cell tryptase can act on the neurons through PAR2. Mast cells can be reactivated by its own mediators in an autocrine and paracrine manner and exacerbate neuroinflammatory pathways. α-synuclein or MPP<sup>+</sup> from glia or extracellular Aβ1–42 can activate mast cells to release neuroinflammatory mediators in PD and AD, respectively. Additionally, several inflammatory mediators from peripheral tissue can alter BBB, enter the brain and activate various neuroinflammatory pathways. Furthermore, inflammatory mediators released from activated microglia and astrocytes enter into peripheral system through defective BBB, activate, and recruit immune and inflammatory cells towards the inflammatory site in the brain. However, the influence of peripheral factors on neuroinflammation could vary from individual to individual and time to time in the same individual, which is much like the situation where some people develop allergic reactions in a given place, even though all people living in that area are exposed to the same external environment such as pollen in the spring. Additionally, the severity and the duration of allergic reactions also varies in these people. Another example is the cancer metastasis to the brain. Metastasis of cancer also varies from person to person based on the immune condition of patients. This is because; mast cell numbers and the extent of mast cell activation-mediated disease severity also varies from person to person.</p>
</sec>
<sec id="s9">
<title>Future Direction</title>
<sec id="s9-1">
<title>A New Approach Is Required to Slow Down the Neuronal Aging Process and Enhance the Neuronal Repair Processes to Treat Neurodegenerative Diseases</title>
<p>Regeneration of the neuronal tissue is limited following any CNS injury. The role of neurite outgrowth inhibitors such as Nogo proteins in inhibiting the neuro regeneration has been reported (Wang et al., <xref ref-type="bibr" rid="B204">2012</xref>). However, in order to achieve efficacious treatment options for the neurodegenerative diseases, it is necessary to explore newer approaches to slowdown the aging process of neurons, replace the dead neurons with the new neurons, and also to repair partially damaged neurons by self-recovery/regenerative mechanisms. Our current knowledge on the interactions between the peripheral immune and inflammatory components with the neuroinflammatory mechanism is still limited (Holmes and Butchart, <xref ref-type="bibr" rid="B63">2011</xref>). Currently most of the laboratories working on the neurodegenerative diseases are dealing primarily with the brain mechanisms but not on the bidirectional communications with the peripheral immune and inflammatory mechanisms. Future research should explore the option for the adult neurons to multiply, grow and make neuronal connections in the adult CNS as seen in the fetal stage. A potentially beneficial approach would be to harness the unlimited potential of patient-specific induced pluripotent stem cells to generate various types of neurons for treatment of neurodegenerative diseases. Multiple inflammatory mediators and multiple immune/inflammatory cells such as mast cells are involved in the pathogenesis of neurodegenerative diseases. A better understanding of the brain and the peripheral immune and inflammatory intertwined pathways is imperative for the effective therapies of brain repair and regeneration.</p>
</sec>
</sec>
<sec id="s10" sec-type="conclusion">
<title>Conclusion</title>
<p>Although the mechanisms of neuroinflammation mediated neurodegeneration is not yet clearly understood, neuroinflammation is considered an important contributing factor for the neuronal death in the brain of age-related neurodegenerative disease. Peripheral immune response/activation and peripheral inflammation could generate several proinflammatory and neuro cytotoxic mediators. These peripheral inflammatory factors as well as peripheral inflammatory cells such as mast cells and T cells enter the brain. Further, these cells and inflammatory mediators could directly or through astrocyte, microglia, neurons and mast cell activation induce and sustain chronic neuroinflammation leading to neuronal death in the brain. Although suppression of neuroinflammation could reduce the severity of disease symptoms and neurodegeneration, the aging factor and immune disorder could continue to influence neurodegeneration. Therefore, novel approaches are required to better understand the communication pathways between the systemic and CNS immune system for the development of new and effective strategies to limit neurodegeneration and promote neuroregeneration in the brain.</p>
</sec>
<sec id="s11">
<title>Author Contributions</title>
<p>DK and AZ wrote and critically edited the manuscript. RT, GPS, SZ, MEA, SPR, HZ, DS, PAN and SI edited the manuscript.</p>
</sec>
<sec id="s12">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>This study was carried out by research grants from the Veteran Affairs Merit Award I01BX002477, and the National Institutes of Health Grants AG048205 and NS073670 to AZ.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>N. J.</given-names></name></person-group> (<year>2000</year>). <article-title>Inflammatory mediators and modulation of blood-brain barrier permeability</article-title>. <source/>Cell. Mol. Neurobiol.
<volume>20</volume>, <fpage>131</fpage>–<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1023/A:1007074420772</pub-id><pub-id pub-id-type="pmid">10696506</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aerbajinai</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Chin</surname><given-names>K.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Parent</surname><given-names>C. A.</given-names></name><name><surname>Rodgers</surname><given-names>G. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Glia maturation factor-γ mediates neutrophil chemotaxis</article-title>. <source/>J. Leukoc. Biol.
<volume>90</volume>, <fpage>529</fpage>–<lpage>538</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0710424</pub-id><pub-id pub-id-type="pmid">21653232</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aheng</surname><given-names>C.</given-names></name><name><surname>Ly</surname><given-names>N.</given-names></name><name><surname>Kelly</surname><given-names>M.</given-names></name><name><surname>Ibrahim</surname><given-names>S.</given-names></name><name><surname>Ricquier</surname><given-names>D.</given-names></name><name><surname>Alves-Guerra</surname><given-names>M. C.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Deletion of UCP2 in iNOS deficient mice reduces the severity of the disease during experimental autoimmune encephalomyelitis</article-title>. <source/>PLoS One
<volume>6</volume>:<fpage>e22841</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0022841</pub-id><pub-id pub-id-type="pmid">21857957</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>S. M.</given-names></name><name><surname>Rothwell</surname><given-names>N. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Cytokines and acute neurodegeneration</article-title>. <source/>Nat. Rev. Neurosci.
<volume>2</volume>, <fpage>734</fpage>–<lpage>744</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4000223</pub-id><pub-id pub-id-type="pmid">11584311</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>S. M.</given-names></name><name><surname>Rothwell</surname><given-names>N. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Inflammation in central nervous system injury</article-title>. <source/>Philos. Trans. R. Soc. Lond. B Biol. Sci.
<volume>358</volume>, <fpage>1669</fpage>–<lpage>1677</lpage>. <pub-id pub-id-type="doi">10.1098/rstb.2003.1358</pub-id><pub-id pub-id-type="pmid">14561325</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>S. M.</given-names></name><name><surname>Tyrrell</surname><given-names>P. J.</given-names></name><name><surname>Rothwell</surname><given-names>N. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Interleukin-1 and neuronal injury</article-title>. <source/>Nat. Rev. Immunol.
<volume>5</volume>, <fpage>629</fpage>–<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1038/nri1664</pub-id><pub-id pub-id-type="pmid">16034365</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alysandratos</surname><given-names>K. D.</given-names></name><name><surname>Asadi</surname><given-names>S.</given-names></name><name><surname>Angelidou</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Sismanopoulos</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Neurotensin and CRH interactions augment human mast cell activation</article-title>. <source/>PLoS One
<volume>7</volume>:<fpage>e48934</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0048934</pub-id><pub-id pub-id-type="pmid">23155429</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>Z. B.</given-names></name><name><surname>Horvath</surname><given-names>B.</given-names></name><name><surname>Barnstable</surname><given-names>C. J.</given-names></name><name><surname>Elsworth</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson’s disease</article-title>. <source/>J. Neurosci.
<volume>25</volume>, <fpage>184</fpage>–<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4269-04.2005</pub-id><pub-id pub-id-type="pmid">15634780</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anisman</surname><given-names>H.</given-names></name><name><surname>Hayley</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Inflammatory factors contribute to depression and its comorbid conditions</article-title>. <source/>Sci. Signal.
<volume>5</volume>:<fpage>pe45</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.2003579</pub-id><pub-id pub-id-type="pmid">23033537</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anisman</surname><given-names>H.</given-names></name><name><surname>Hayley</surname><given-names>S.</given-names></name><name><surname>Turrin</surname><given-names>N.</given-names></name><name><surname>Merali</surname><given-names>Z.</given-names></name></person-group> (<year>2002</year>). <article-title>Cytokines as a stressor: implications for depressive illness</article-title>. <source/>Int. J. Neuropsychopharmacol.
<volume>5</volume>, <fpage>357</fpage>–<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1017/s1461145702003097</pub-id><pub-id pub-id-type="pmid">12466035</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asadi</surname><given-names>S.</given-names></name><name><surname>Alysandratos</surname><given-names>K. D.</given-names></name><name><surname>Angelidou</surname><given-names>A.</given-names></name><name><surname>Miniati</surname><given-names>A.</given-names></name><name><surname>Sismanopoulos</surname><given-names>N.</given-names></name><name><surname>Vasiadi</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells</article-title>. <source/>J. Invest. Dermatol.
<volume>132</volume>, <fpage>324</fpage>–<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1038/jid.2011.334</pub-id><pub-id pub-id-type="pmid">22089831</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascolani</surname><given-names>A.</given-names></name><name><surname>Balestrieri</surname><given-names>E.</given-names></name><name><surname>Minutolo</surname><given-names>A.</given-names></name><name><surname>Mosti</surname><given-names>S.</given-names></name><name><surname>Spalletta</surname><given-names>G.</given-names></name><name><surname>Bramanti</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Dysregulated NF-κB pathway in peripheral mononuclear cells of Alzheimer’s disease patients</article-title>. <source/>Curr. Alzheimer Res.
<volume>9</volume>, <fpage>128</fpage>–<lpage>137</lpage>. <pub-id pub-id-type="doi">10.2174/156720512799015091</pub-id><pub-id pub-id-type="pmid">21592054</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzolina</surname><given-names>A.</given-names></name><name><surname>Bongiovanni</surname><given-names>A.</given-names></name><name><surname>Lampiasi</surname><given-names>N.</given-names></name></person-group> (<year>2003</year>). <article-title>Substance P induces TNF-α and IL-6 production through NF-κB in peritoneal mast cells</article-title>. <source/>Biochim. Biophys. Acta
<volume>1643</volume>, <fpage>75</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2003.09.003</pub-id><pub-id pub-id-type="pmid">14654230</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>W. A.</given-names></name><name><surname>Kastin</surname><given-names>A. J.</given-names></name><name><surname>Broadwell</surname><given-names>R. D.</given-names></name></person-group> (<year>1995</year>). <article-title>Passage of cytokines across the blood-brain barrier</article-title>. <source/>Neuroimmunomodulation
<volume>2</volume>, <fpage>241</fpage>–<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1159/000097202</pub-id><pub-id pub-id-type="pmid">8963753</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becher</surname><given-names>B.</given-names></name><name><surname>Spath</surname><given-names>S.</given-names></name><name><surname>Goverman</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Cytokine networks in neuroinflammation</article-title>. <source/>Nat. Rev. Immunol.
<volume>17</volume>, <fpage>49</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2016.123</pub-id><pub-id pub-id-type="pmid">27916979</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Béraud</surname><given-names>D.</given-names></name><name><surname>Hathaway</surname><given-names>H. A.</given-names></name><name><surname>Trecki</surname><given-names>J.</given-names></name><name><surname>Chasovskikh</surname><given-names>S.</given-names></name><name><surname>Johnson</surname><given-names>D. A.</given-names></name><name><surname>Johnson</surname><given-names>J. A.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Microglial activation and antioxidant responses induced by the Parkinson’s disease protein α-synuclein</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>8</volume>, <fpage>94</fpage>–<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-012-9401-0</pub-id><pub-id pub-id-type="pmid">23054368</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisaglia</surname><given-names>M.</given-names></name><name><surname>Filograna</surname><given-names>R.</given-names></name><name><surname>Beltramini</surname><given-names>M.</given-names></name><name><surname>Bubacco</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Are dopamine derivatives implicated in the pathogenesis of Parkinson’s disease?</article-title>
<source/>Ageing Res. Rev.
<volume>13C</volume>, <fpage>107</fpage>–<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2013.12.009</pub-id><pub-id pub-id-type="pmid">24389159</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>M. L.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Qin</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Pei</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin</article-title>. <source/>FASEB J.
<volume>20</volume>, <fpage>251</fpage>–<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1096/fj.05-4553com</pub-id><pub-id pub-id-type="pmid">16449797</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum-Degen</surname><given-names>D.</given-names></name><name><surname>Müller</surname><given-names>T.</given-names></name><name><surname>Kuhn</surname><given-names>W.</given-names></name><name><surname>Gerlach</surname><given-names>M.</given-names></name><name><surname>Przuntek</surname><given-names>H.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name></person-group> (<year>1995</year>). <article-title>Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and <italic>de novo</italic> Parkinson’s disease patients</article-title>. <source/>Neurosci. Lett.
<volume>202</volume>, <fpage>17</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3940(95)12192-7</pub-id><pub-id pub-id-type="pmid">8787820</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollaerts</surname><given-names>I.</given-names></name><name><surname>Van Houcke</surname><given-names>J.</given-names></name><name><surname>Andries</surname><given-names>L.</given-names></name><name><surname>De Groef</surname><given-names>L.</given-names></name><name><surname>Moons</surname><given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>Neuroinflammation as fuel for axonal regeneration in the injured vertebrate central nervous system</article-title>. <source/>Mediators Inflamm.
<volume>2017</volume>:<fpage>9478542</fpage>. <pub-id pub-id-type="doi">10.1155/2017/9478542</pub-id><pub-id pub-id-type="pmid">28203046</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bronzuoli</surname><given-names>M. R.</given-names></name><name><surname>Iacomino</surname><given-names>A.</given-names></name><name><surname>Steardo</surname><given-names>L.</given-names></name><name><surname>Scuderi</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>Targeting neuroinflammation in Alzheimer’s disease</article-title>. <source/>J. Inflamm. Res.
<volume>9</volume>, <fpage>199</fpage>–<lpage>208</lpage>. <pub-id pub-id-type="doi">10.2147/JIR.S86958</pub-id><pub-id pub-id-type="pmid">27843334</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brough</surname><given-names>D.</given-names></name><name><surname>Rothwell</surname><given-names>N. J.</given-names></name><name><surname>Allan</surname><given-names>S. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Interleukin-1 as a pharmacological target in acute brain injury</article-title>. <source/>Exp. Physiol.
<volume>100</volume>, <fpage>1488</fpage>–<lpage>1494</lpage>. <pub-id pub-id-type="doi">10.1113/EP085135</pub-id><pub-id pub-id-type="pmid">26096539</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>M. A.</given-names></name><name><surname>Hatfield</surname><given-names>J. K.</given-names></name></person-group> (<year>2012</year>). <article-title>Mast cells are important modifiers of autoimmune disease: with so much evidence, why is there still controversy?</article-title>
<source/>Front. Immunol.
<volume>3</volume>:<fpage>147</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2012.00147</pub-id><pub-id pub-id-type="pmid">22701454</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Papadopoulou</surname><given-names>N.</given-names></name><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Boucher</surname><given-names>W. S.</given-names></name><name><surname>Sugimoto</surname><given-names>K.</given-names></name><name><surname>Cetrulo</surname><given-names>C. L.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor</article-title>. <source/>J. Immunol.
<volume>174</volume>, <fpage>7665</fpage>–<lpage>7675</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.174.12.7665</pub-id><pub-id pub-id-type="pmid">15944267</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>S.</given-names></name><name><surname>Correia</surname><given-names>S.</given-names></name><name><surname>Carvalho</surname><given-names>C.</given-names></name><name><surname>Candeias</surname><given-names>E.</given-names></name><name><surname>Placido</surname><given-names>A. I.</given-names></name><name><surname>Duarte</surname><given-names>A. I.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Perspectives on mitochondrial uncoupling proteins-mediated neuroprotection</article-title>. <source/>J. Bioenerg. Biomembr.
<volume>47</volume>, <fpage>119</fpage>–<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1007/s10863-014-9580-x</pub-id><pub-id pub-id-type="pmid">25217852</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>A. L.</given-names></name><name><surname>Guedes</surname><given-names>J. R.</given-names></name><name><surname>Pereira De Almeida</surname><given-names>L.</given-names></name><name><surname>Pedroso De Lima</surname><given-names>M. C.</given-names></name></person-group> (<year>2012</year>). <article-title>miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production</article-title>. <source/>Immunology
<volume>135</volume>, <fpage>73</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2567.2011.03514.x</pub-id><pub-id pub-id-type="pmid">22043967</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.-W.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>W.-J.</given-names></name></person-group> (<year>2016</year>). <article-title>Role of neuroinflammation in neurodegenerative diseases (Review)</article-title>. <source/>Mol. Med. Rep.
<volume>13</volume>, <fpage>3391</fpage>–<lpage>3396</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2016.4948</pub-id><pub-id pub-id-type="pmid">26935478</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chikahisa</surname><given-names>S.</given-names></name><name><surname>Kodama</surname><given-names>T.</given-names></name><name><surname>Soya</surname><given-names>A.</given-names></name><name><surname>Sagawa</surname><given-names>Y.</given-names></name><name><surname>Ishimaru</surname><given-names>Y.</given-names></name><name><surname>Sei</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Histamine from brain resident MAST cells promotes wakefulness and modulates behavioral states</article-title>. <source/>PLoS One
<volume>8</volume>:<fpage>e78434</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0078434</pub-id><pub-id pub-id-type="pmid">24205232</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>Y. C.</given-names></name><name><surname>Ko</surname><given-names>H. W.</given-names></name><name><surname>Bok</surname><given-names>E.</given-names></name><name><surname>Park</surname><given-names>E. S.</given-names></name><name><surname>Huh</surname><given-names>S. H.</given-names></name><name><surname>Nam</surname><given-names>J. H.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>The role of neuroinflammation on the pathogenesis of Parkinson’s disease</article-title>. <source/>BMB Rep.
<volume>43</volume>, <fpage>225</fpage>–<lpage>232</lpage>. <pub-id pub-id-type="doi">10.5483/BMBRep.2010.43.4.225</pub-id><pub-id pub-id-type="pmid">20423606</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cocchiara</surname><given-names>R.</given-names></name><name><surname>Lampiasi</surname><given-names>N.</given-names></name><name><surname>Albeggiani</surname><given-names>G.</given-names></name><name><surname>Bongiovanni</surname><given-names>A.</given-names></name><name><surname>Azzolina</surname><given-names>A.</given-names></name><name><surname>Geraci</surname><given-names>D.</given-names></name></person-group> (<year>1999</year>). <article-title>Mast cell production of TNF-α induced by substance P evidence for a modulatory role of substance P-antagonists</article-title>. <source/>J. Neuroimmunol.
<volume>101</volume>, <fpage>128</fpage>–<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1016/s0165-5728(99)00138-1</pub-id><pub-id pub-id-type="pmid">10580796</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>P.</given-names></name><name><surname>Kempuraj</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>Important role of mast cells in multiple sclerosis</article-title>. <source/>Mult. Scler. Relat. Disord.
<volume>5</volume>, <fpage>77</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.msard.2015.11.005</pub-id><pub-id pub-id-type="pmid">26856948</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culley</surname><given-names>D. J.</given-names></name><name><surname>Snayd</surname><given-names>M.</given-names></name><name><surname>Baxter</surname><given-names>M. G.</given-names></name><name><surname>Xie</surname><given-names>Z.</given-names></name><name><surname>Lee</surname><given-names>I. H.</given-names></name><name><surname>Rudolph</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Systemic inflammation impairs attention and cognitive flexibility but not associative learning in aged rats: possible implications for delirium</article-title>. <source/>Front. Aging Neurosci.
<volume>6</volume>:<fpage>107</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2014.00107</pub-id><pub-id pub-id-type="pmid">24959140</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>C.</given-names></name><name><surname>Campion</surname><given-names>S.</given-names></name><name><surname>Lunnon</surname><given-names>K.</given-names></name><name><surname>Murray</surname><given-names>C. L.</given-names></name><name><surname>Woods</surname><given-names>J. F.</given-names></name><name><surname>Deacon</surname><given-names>R. M.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease</article-title>. <source/>Biol. Psychiatry
<volume>65</volume>, <fpage>304</fpage>–<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.07.024</pub-id><pub-id pub-id-type="pmid">18801476</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantzer</surname><given-names>R.</given-names></name><name><surname>Konsman</surname><given-names>J. P.</given-names></name><name><surname>Bluthé</surname><given-names>R. M.</given-names></name><name><surname>Kelley</surname><given-names>K. W.</given-names></name></person-group> (<year>2000</year>). <article-title>Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent?</article-title>
<source/>Auton. Neurosci.
<volume>85</volume>, <fpage>60</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/s1566-0702(00)00220-4</pub-id><pub-id pub-id-type="pmid">11189027</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dedic</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>A.</given-names></name><name><surname>Deussing</surname><given-names>J. M.</given-names></name></person-group> (<year>2017</year>). <article-title>The CRF family of neuropeptides and their receptors—mediators of the central stress response</article-title>. <source/>Curr. Mol. Pharmacol. [Epub ahead of print]. <pub-id pub-id-type="doi">10.2174/1874467210666170302104053</pub-id><pub-id pub-id-type="pmid">28260504</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dendrou</surname><given-names>C. A.</given-names></name><name><surname>McVean</surname><given-names>G.</given-names></name><name><surname>Fugger</surname><given-names>L.</given-names></name></person-group> (<year>2016</year>). <article-title>Neuroinflammation—using big data to inform clinical practice</article-title>. <source/>Nat. Rev. Neurol.
<volume>12</volume>, <fpage>685</fpage>–<lpage>698</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2016.171</pub-id><pub-id pub-id-type="pmid">27857124</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Pablos</surname><given-names>R. M.</given-names></name><name><surname>Herrera</surname><given-names>A. J.</given-names></name><name><surname>Espinosa-Oliva</surname><given-names>A. M.</given-names></name><name><surname>Sarmiento</surname><given-names>M.</given-names></name><name><surname>Muñoz</surname><given-names>M. F.</given-names></name><name><surname>Machado</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Chronic stress enhances microglia activation and exacerbates death of nigral dopaminergic neurons under conditions of inflammation</article-title>. <source/>J. Neuroinflammation
<volume>11</volume>:<fpage>34</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-11-34</pub-id><pub-id pub-id-type="pmid">24565378</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Simone</surname><given-names>R.</given-names></name><name><surname>Ajmone-Cat</surname><given-names>M. A.</given-names></name><name><surname>Pandolfi</surname><given-names>M.</given-names></name><name><surname>Bernardo</surname><given-names>A.</given-names></name><name><surname>De Nuccio</surname><given-names>C.</given-names></name><name><surname>Minghetti</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>The mitochondrial uncoupling protein-2 is a master regulator of both M1 and M2 microglial responses</article-title>. <source/>J. Neurochem.
<volume>135</volume>, <fpage>147</fpage>–<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13244</pub-id><pub-id pub-id-type="pmid">26173855</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desplats</surname><given-names>P.</given-names></name><name><surname>Lee</surname><given-names>H.-J.</given-names></name><name><surname>Bae</surname><given-names>E.-J.</given-names></name><name><surname>Patrick</surname><given-names>C.</given-names></name><name><surname>Rockenstein</surname><given-names>E.</given-names></name><name><surname>Crews</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>106</volume>, <fpage>13010</fpage>–<lpage>13015</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0903691106</pub-id><pub-id pub-id-type="pmid">19651612</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Mast cells and neuroinflammation</article-title>. <source/>Med. Sci. Monit. Basic Res.
<volume>20</volume>, <fpage>200</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.12659/MSMBR.893093</pub-id><pub-id pub-id-type="pmid">25529562</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ek</surname><given-names>M.</given-names></name><name><surname>Engblom</surname><given-names>D.</given-names></name><name><surname>Saha</surname><given-names>S.</given-names></name><name><surname>Blomqvist</surname><given-names>A.</given-names></name><name><surname>Jakobsson</surname><given-names>P. J.</given-names></name><name><surname>Ericsson-Dahlstrand</surname><given-names>A.</given-names></name></person-group> (<year>2001</year>). <article-title>Inflammatory response: pathway across the blood-brain barrier</article-title>. <source/>Nature
<volume>410</volume>, <fpage>430</fpage>–<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1038/35068632</pub-id><pub-id pub-id-type="pmid">11260702</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelhardt</surname><given-names>B.</given-names></name><name><surname>Vajkoczy</surname><given-names>P.</given-names></name><name><surname>Weller</surname><given-names>R. O.</given-names></name></person-group> (<year>2017</year>). <article-title>The movers and shapers in immune privilege of the CNS</article-title>. <source/>Nat. Immunol.
<volume>18</volume>, <fpage>123</fpage>–<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3666</pub-id><pub-id pub-id-type="pmid">28092374</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enoksson</surname><given-names>M.</given-names></name><name><surname>Lyberg</surname><given-names>K.</given-names></name><name><surname>Moller-Westerberg</surname><given-names>C.</given-names></name><name><surname>Fallon</surname><given-names>P. G.</given-names></name><name><surname>Nilsson</surname><given-names>G.</given-names></name><name><surname>Lunderius-Andersson</surname><given-names>C.</given-names></name></person-group> (<year>2011</year>). <article-title>Mast cells as sensors of cell injury through IL-33 recognition</article-title>. <source/>J. Immunol.
<volume>186</volume>, <fpage>2523</fpage>–<lpage>2528</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1003383</pub-id><pub-id pub-id-type="pmid">21239713</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espinosa-Oliva</surname><given-names>A. M.</given-names></name><name><surname>De Pablos</surname><given-names>R. M.</given-names></name><name><surname>Sarmiento</surname><given-names>M.</given-names></name><name><surname>Villarán</surname><given-names>R. F.</given-names></name><name><surname>Carrillo-Jiménez</surname><given-names>A.</given-names></name><name><surname>Santiago</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Role of dopamine in the recruitment of immune cells to the nigro-striatal dopaminergic structures</article-title>. <source/>Neurotoxicology
<volume>41</volume>, <fpage>89</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuro.2014.01.006</pub-id><pub-id pub-id-type="pmid">24486959</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>P.</given-names></name><name><surname>Chandler</surname><given-names>N.</given-names></name><name><surname>Kandere</surname><given-names>K.</given-names></name><name><surname>Basu</surname><given-names>S.</given-names></name><name><surname>Jacobson</surname><given-names>S.</given-names></name><name><surname>Connolly</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2002</year>). <article-title>Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress</article-title>. <source/>J. Pharmacol. Exp. Ther.
<volume>303</volume>, <fpage>1061</fpage>–<lpage>1066</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.102.038497</pub-id><pub-id pub-id-type="pmid">12438528</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>A.</given-names></name><name><surname>de Ceballos</surname><given-names>M. L.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name><name><surname>Marsden</surname><given-names>C. D.</given-names></name></person-group> (<year>1992</year>). <article-title>Striatal neuropeptide levels in Parkinson’s disease patients</article-title>. <source/>Neurosci. Lett.
<volume>145</volume>, <fpage>171</fpage>–<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3940(92)90014-x</pub-id><pub-id pub-id-type="pmid">1281532</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>C. C.</given-names></name><name><surname>Tarelli</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Parkinson’s disease and systemic inflammation</article-title>. <source/>Parkinsons Dis.
<volume>2011</volume>:<fpage>436813</fpage>. <pub-id pub-id-type="doi">10.4061/2011/436813</pub-id><pub-id pub-id-type="pmid">21403862</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>J. G.</given-names></name><name><surname>Ryan</surname><given-names>J. J.</given-names></name><name><surname>Shelburne</surname><given-names>C. P.</given-names></name><name><surname>Bailey</surname><given-names>D. P.</given-names></name><name><surname>Bouton</surname><given-names>L. A.</given-names></name><name><surname>Narasimhachari</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Catecholamines in murine bone marrow derived mast cells</article-title>. <source/>J. Neuroimmunol.
<volume>119</volume>, <fpage>231</fpage>–<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1016/S0165-5728(01)00384-8</pub-id><pub-id pub-id-type="pmid">11585626</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname><given-names>S. J.</given-names></name><name><surname>Grimbaldeston</surname><given-names>M.</given-names></name><name><surname>Tsai</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Immunomodulatory mast cells: negative, as well as positive, regulators of immunity</article-title>. <source/>Nat. Rev. Immunol.
<volume>8</volume>, <fpage>478</fpage>–<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1038/nri2327</pub-id><pub-id pub-id-type="pmid">18483499</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibb</surname><given-names>J.</given-names></name><name><surname>Audet</surname><given-names>M. C.</given-names></name><name><surname>Hayley</surname><given-names>S.</given-names></name><name><surname>Anisman</surname><given-names>H.</given-names></name></person-group> (<year>2009</year>). <article-title>Neurochemical and behavioral responses to inflammatory immune stressors</article-title>. <source/>Front. Biosci. (Schol. Ed.)
<volume>1</volume>, <fpage>275</fpage>–<lpage>295</lpage>. <pub-id pub-id-type="doi">10.2741/e26</pub-id><pub-id pub-id-type="pmid">19482702</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilfillan</surname><given-names>A. M.</given-names></name><name><surname>Austin</surname><given-names>S. J.</given-names></name><name><surname>Metcalfe</surname><given-names>D. D.</given-names></name></person-group> (<year>2011</year>). <article-title>Mast cell biology: introduction and overview</article-title>. <source/>Adv. Exp. Med. Biol.
<volume>716</volume>, <fpage>2</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4419-9533-9_1</pub-id><pub-id pub-id-type="pmid">21713648</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldeck</surname><given-names>D.</given-names></name><name><surname>Witkowski</surname><given-names>J. M.</given-names></name><name><surname>Fülop</surname><given-names>T.</given-names></name><name><surname>Pawelec</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Peripheral immune signatures in Alzheimer disease</article-title>. <source/>Curr. Alzheimer Res.
<volume>13</volume>, <fpage>739</fpage>–<lpage>749</lpage>. <pub-id pub-id-type="doi">10.2174/1567205013666160222112444</pub-id><pub-id pub-id-type="pmid">26899580</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>D. K.</given-names></name><name><surname>Spinas</surname><given-names>E.</given-names></name><name><surname>Kritas</surname><given-names>S. K.</given-names></name><name><surname>Saggini</surname><given-names>A.</given-names></name><name><surname>Caraffa</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Role of TNF in mast cell neuroinflammation and pain</article-title>. <source/>J. Biol. Regul. Homeost. Agents
<volume>29</volume>, <fpage>787</fpage>–<lpage>791</lpage>. <pub-id pub-id-type="pmid">26753638</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gualtierotti</surname><given-names>R.</given-names></name><name><surname>Guarnaccia</surname><given-names>L.</given-names></name><name><surname>Beretta</surname><given-names>M.</given-names></name><name><surname>Navone</surname><given-names>S. E.</given-names></name><name><surname>Campanella</surname><given-names>R.</given-names></name><name><surname>Riboni</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Modulation of neuroinflammation in the central nervous system: role of chemokines and sphingolipids</article-title>. <source/>Adv. Ther.
<volume>34</volume>, <fpage>396</fpage>–<lpage>420</lpage>. <pub-id pub-id-type="doi">10.1007/s12325-016-0474-7</pub-id><pub-id pub-id-type="pmid">28054310</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurish</surname><given-names>M. F.</given-names></name><name><surname>Austen</surname><given-names>K. F.</given-names></name></person-group> (<year>2001</year>). <article-title>The diverse roles of mast cells</article-title>. <source/>J. Exp. Med.
<volume>194</volume>, <fpage>F1</fpage>–<lpage>F5</lpage>. <pub-id pub-id-type="doi">10.1084/jem.194.1.f1</pub-id><pub-id pub-id-type="pmid">11435478</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamke</surname><given-names>M.</given-names></name><name><surname>Herpfer</surname><given-names>I.</given-names></name><name><surname>Lieb</surname><given-names>K.</given-names></name><name><surname>Wandelt</surname><given-names>C.</given-names></name><name><surname>Fiebich</surname><given-names>B. L.</given-names></name></person-group> (<year>2006</year>). <article-title>Substance P induces expression of the corticotropin-releasing factor receptor 1 by activation of the neurokinin-1 receptor</article-title>. <source/>Brain Res.
<volume>1102</volume>, <fpage>135</fpage>–<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2006.03.026</pub-id><pub-id pub-id-type="pmid">16806114</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayley</surname><given-names>S.</given-names></name><name><surname>Anisman</surname><given-names>H.</given-names></name></person-group> (<year>2005</year>). <article-title>Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states: neurochemical and molecular substrates</article-title>. <source/>Curr. Pharm. Des.
<volume>11</volume>, <fpage>947</fpage>–<lpage>962</lpage>. <pub-id pub-id-type="doi">10.2174/1381612053381611</pub-id><pub-id pub-id-type="pmid">15777246</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayley</surname><given-names>S.</given-names></name><name><surname>Scharf</surname><given-names>J.</given-names></name><name><surname>Anisman</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>Central administration of murine interferon-α induces depressive-like behavioral, brain cytokine and neurochemical alterations in mice: a mini-review and original experiments</article-title>. <source/>Brain Behav. Immun.
<volume>31</volume>, <fpage>115</fpage>–<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2012.07.023</pub-id><pub-id pub-id-type="pmid">22884959</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Yuan</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Downregulation of miR-7116–5p in microglia by MPP<sup>+</sup> sensitizes TNF-α production to induce dopaminergic neuron damage</article-title>. <source/>Glia
<volume>65</volume>, <fpage>1251</fpage>–<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1002/glia.23153</pub-id><pub-id pub-id-type="pmid">28543680</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández-Romero</surname><given-names>M. C.</given-names></name><name><surname>Delgado-Cortés</surname><given-names>M. J.</given-names></name><name><surname>Sarmiento</surname><given-names>M.</given-names></name><name><surname>de Pablos</surname><given-names>R. M.</given-names></name><name><surname>Espinosa-Oliva</surname><given-names>A. M.</given-names></name><name><surname>Argüelles</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system</article-title>. <source/>Neurotoxicology
<volume>33</volume>, <fpage>347</fpage>–<lpage>360</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuro.2012.01.018</pub-id><pub-id pub-id-type="pmid">22330755</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Héron</surname><given-names>A.</given-names></name><name><surname>Dubayle</surname><given-names>D.</given-names></name></person-group> (<year>2013</year>). <article-title>A focus on mast cells and pain</article-title>. <source/>J. Neuroimmunol.
<volume>264</volume>, <fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2013.09.018</pub-id><pub-id pub-id-type="pmid">24125568</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>P. W.</given-names></name><name><surname>Ho</surname><given-names>J. W.</given-names></name><name><surname>Liu</surname><given-names>H.-F.</given-names></name><name><surname>So</surname><given-names>D. H.</given-names></name><name><surname>Tse</surname><given-names>Z. H.</given-names></name><name><surname>Chan</surname><given-names>K. H.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Mitochondrial neuronal uncoupling proteins: a target for potential disease-modification in Parkinson’s disease</article-title>. <source/>Transl. Neurodegener.
<volume>1</volume>:<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/2047-9158-1-3</pub-id><pub-id pub-id-type="pmid">23210978</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>C.</given-names></name><name><surname>Butchart</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Systemic inflammation and Alzheimer’s disease</article-title>. <source/>Biochem. Soc. Trans.
<volume>39</volume>, <fpage>898</fpage>–<lpage>901</lpage>. <pub-id pub-id-type="doi">10.1042/BST0390898</pub-id><pub-id pub-id-type="pmid">21787320</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>C.</given-names></name><name><surname>Cunningham</surname><given-names>C.</given-names></name><name><surname>Zotova</surname><given-names>E.</given-names></name><name><surname>Woolford</surname><given-names>J.</given-names></name><name><surname>Dean</surname><given-names>C.</given-names></name><name><surname>Kerr</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Systemic inflammation and disease progression in Alzheimer disease</article-title>. <source/>Neurology
<volume>73</volume>, <fpage>768</fpage>–<lpage>774</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181b6bb95</pub-id><pub-id pub-id-type="pmid">19738171</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>C.</given-names></name><name><surname>El-Okl</surname><given-names>M.</given-names></name><name><surname>Williams</surname><given-names>A. L.</given-names></name><name><surname>Cunningham</surname><given-names>C.</given-names></name><name><surname>Wilcockson</surname><given-names>D.</given-names></name><name><surname>Perry</surname><given-names>V. H.</given-names></name></person-group> (<year>2003</year>). <article-title>Systemic infection, interleukin 1β, and cognitive decline in Alzheimer’s disease</article-title>. <source/>J. Neurol. Neurosurg. Psychiatry
<volume>74</volume>, <fpage>788</fpage>–<lpage>789</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp.74.6.788</pub-id><pub-id pub-id-type="pmid">12754353</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogland</surname><given-names>I. C.</given-names></name><name><surname>Houbolt</surname><given-names>C.</given-names></name><name><surname>Van Westerloo</surname><given-names>D. J.</given-names></name><name><surname>van Gool</surname><given-names>W. A.</given-names></name><name><surname>van de Beek</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Systemic inflammation and microglial activation: systematic review of animal experiments</article-title>. <source/>J. Neuroinflammation
<volume>12</volume>:<fpage>114</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-015-0332-6</pub-id><pub-id pub-id-type="pmid">26048578</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horak</surname><given-names>J.</given-names></name><name><surname>Dincer</surname><given-names>C.</given-names></name><name><surname>Bakirci</surname><given-names>H.</given-names></name><name><surname>Urban</surname><given-names>G.</given-names></name></person-group> (<year>2014</year>). <article-title>Sensitive, rapid and quantitative detection of substance P in serum samples using an integrated microfluidic immunochip</article-title>. <source/>Biosens Bioelectron.
<volume>58C</volume>, <fpage>186</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/j.bios.2014.02.058</pub-id><pub-id pub-id-type="pmid">24637167</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hösli</surname><given-names>L.</given-names></name><name><surname>Hösli</surname><given-names>E.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name><name><surname>Wiget</surname><given-names>W.</given-names></name></person-group> (<year>1984</year>). <article-title>Evidence for the existence of histamine H1- and H2-receptors on astrocytes of cultured rat central nervous system</article-title>. <source/>Neurosci. Lett.
<volume>48</volume>, <fpage>287</fpage>–<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3940(84)90052-1</pub-id><pub-id pub-id-type="pmid">6148726</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>K.</given-names></name><name><surname>Kundu</surname><given-names>R. K.</given-names></name><name><surname>Ikeda</surname><given-names>S.</given-names></name><name><surname>Kobara</surname><given-names>M.</given-names></name><name><surname>Matsubara</surname><given-names>H.</given-names></name><name><surname>Quertermous</surname><given-names>T.</given-names></name></person-group> (<year>2006</year>). <article-title>Glia maturation factor-γ is preferentially expressed in microvascular endothelial and inflammatory cells and modulates actin cytoskeleton reorganization</article-title>. <source/>Circ. Res.
<volume>99</volume>, <fpage>424</fpage>–<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1161/01.res.0000237662.23539.0b</pub-id><pub-id pub-id-type="pmid">16873721</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>R.</given-names></name><name><surname>Asai</surname><given-names>K.</given-names></name><name><surname>Hanai</surname><given-names>J.</given-names></name><name><surname>Takenaka</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Transgenic mice overexpressing glia maturation factor-β, an oxidative stress inducible gene, show premature aging due to Zmpste24 down-regulation</article-title>. <source/>Aging
<volume>7</volume>, <fpage>486</fpage>–<lpage>499</lpage>. <pub-id pub-id-type="doi">10.18632/aging.100779</pub-id><pub-id pub-id-type="pmid">26232943</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>P.</given-names></name><name><surname>Almqvist</surname><given-names>E. G.</given-names></name><name><surname>Wallin</surname><given-names>A.</given-names></name><name><surname>Johansson</surname><given-names>J. O.</given-names></name><name><surname>Andreasson</surname><given-names>U.</given-names></name><name><surname>Blennow</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer’s disease</article-title>. <source/>Neurosci. Lett.
<volume>609</volume>, <fpage>58</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2015.10.006</pub-id><pub-id pub-id-type="pmid">26453765</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>R. W.</given-names></name><name><surname>Arkins</surname><given-names>S.</given-names></name><name><surname>Dantzer</surname><given-names>R.</given-names></name><name><surname>Kelley</surname><given-names>K. W.</given-names></name></person-group> (<year>1997</year>). <article-title>Hormones, lymphohemopoietic cytokines and the neuroimmune axis</article-title>. <source/>Comp. Biochem. Physiol. A Physiol.
<volume>116</volume>, <fpage>183</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/s0300-9629(96)00277-0</pub-id><pub-id pub-id-type="pmid">9102183</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>D.</given-names></name><name><surname>Yasui</surname><given-names>D.</given-names></name><name><surname>Seeldrayers</surname><given-names>P.</given-names></name></person-group> (<year>1991</year>). <article-title>An analysis of mast cell frequency in the rodent nervous system: numbers vary between different strains and can be reconstituted in mast cell-deficient mice</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>50</volume>, <fpage>227</fpage>–<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1097/00005072-199105000-00005</pub-id><pub-id pub-id-type="pmid">2022965</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaimori</surname><given-names>J. Y.</given-names></name><name><surname>Takenaka</surname><given-names>M.</given-names></name><name><surname>Nakajima</surname><given-names>H.</given-names></name><name><surname>Hamano</surname><given-names>T.</given-names></name><name><surname>Horio</surname><given-names>M.</given-names></name><name><surname>Sugaya</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Induction of glia maturation factor-β in proximal tubular cells leads to vulnerability to oxidative injury through the p38 pathway and changes in antioxidant enzyme activities</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>33519</fpage>–<lpage>33527</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m301552200</pub-id><pub-id pub-id-type="pmid">12791701</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalesnikoff</surname><given-names>J.</given-names></name><name><surname>Galli</surname><given-names>S. J.</given-names></name></person-group> (<year>2008</year>). <article-title>New developments in mast cell biology</article-title>. <source/>Nat. Immunol.
<volume>9</volume>, <fpage>1215</fpage>–<lpage>1223</lpage>. <pub-id pub-id-type="doi">10.1038/ni.f.216</pub-id><pub-id pub-id-type="pmid">18936782</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandere-Grzybowska</surname><given-names>K.</given-names></name><name><surname>Letourneau</surname><given-names>R.</given-names></name><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Donelan</surname><given-names>J.</given-names></name><name><surname>Poplawski</surname><given-names>S.</given-names></name><name><surname>Boucher</surname><given-names>W.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells</article-title>. <source/>J. Immunol.
<volume>171</volume>, <fpage>4830</fpage>–<lpage>4836</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.171.9.4830</pub-id><pub-id pub-id-type="pmid">14568962</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>R.</given-names></name><name><surname>Zaheer</surname><given-names>A.</given-names></name><name><surname>Jaye</surname><given-names>M.</given-names></name><name><surname>Lim</surname><given-names>R.</given-names></name></person-group> (<year>1991</year>). <article-title>Molecular cloning and expression of biologically active human glia maturation factor-β</article-title>. <source/>J. Neurochem.
<volume>57</volume>, <fpage>483</fpage>–<lpage>490</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.1991.tb03777.x</pub-id><pub-id pub-id-type="pmid">1712830</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karagkouni</surname><given-names>A.</given-names></name><name><surname>Alevizos</surname><given-names>M.</given-names></name><name><surname>Theoharides</surname><given-names>T. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Effect of stress on brain inflammation and multiple sclerosis</article-title>. <source/>Autoimmun. Rev.
<volume>12</volume>, <fpage>947</fpage>–<lpage>953</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2013.02.006</pub-id><pub-id pub-id-type="pmid">23537508</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsanos</surname><given-names>G. S.</given-names></name><name><surname>Anogeianaki</surname><given-names>A.</given-names></name><name><surname>Orso</surname><given-names>C.</given-names></name><name><surname>Tetè</surname><given-names>S.</given-names></name><name><surname>Salini</surname><given-names>V.</given-names></name><name><surname>Antinolfi</surname><given-names>P. L.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Mast cells and chemokines</article-title>. <source/>J. Biol. Regul. Homeost. Agents
<volume>22</volume>, <fpage>145</fpage>–<lpage>151</lpage>. <pub-id pub-id-type="pmid">18842167</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Devi</surname><given-names>R. S.</given-names></name><name><surname>Madhappan</surname><given-names>B.</given-names></name><name><surname>Conti</surname><given-names>P.</given-names></name><name><surname>Nazer</surname><given-names>M. Y.</given-names></name><name><surname>Christodoulou</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2004a</year>). <article-title>T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment and based on histological type of tumors</article-title>. <source/>Int. J. Immunopathol. Pharmacol.
<volume>17</volume>, <fpage>57</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1177/039463200401700108</pub-id><pub-id pub-id-type="pmid">15000867</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Papadopoulou</surname><given-names>N. G.</given-names></name><name><surname>Lytinas</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Kandere-Grzybowska</surname><given-names>K.</given-names></name><name><surname>Madhappan</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2004b</year>). <article-title>Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells</article-title>. <source/>Endocrinology
<volume>145</volume>, <fpage>43</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1210/en.2003-0805</pub-id><pub-id pub-id-type="pmid">14576187</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Khan</surname><given-names>M. M.</given-names></name><name><surname>Thangavel</surname><given-names>R.</given-names></name><name><surname>Xiong</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>E.</given-names></name><name><surname>Zaheer</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>8</volume>, <fpage>643</fpage>–<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-013-9439-7</pub-id><pub-id pub-id-type="pmid">23397250</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Thangavel</surname><given-names>R.</given-names></name><name><surname>Fattal</surname><given-names>R.</given-names></name><name><surname>Pattani</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>E.</given-names></name><name><surname>Zaheer</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2016a</year>). <article-title>Mast cells release chemokine CCL2 in response to parkinsonian toxin 1-methyl-4-phenyl-pyridinium (MPP<sup>+</sup>)</article-title>. <source/>Neurochem. Res.
<volume>41</volume>, <fpage>1042</fpage>–<lpage>1049</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-015-1790-z</pub-id><pub-id pub-id-type="pmid">26646004</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Thangavel</surname><given-names>R.</given-names></name><name><surname>Natteru</surname><given-names>P. A.</given-names></name><name><surname>Selvakumar</surname><given-names>G. P.</given-names></name><name><surname>Saeed</surname><given-names>D.</given-names></name><name><surname>Zahoor</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2016b</year>). <article-title>Neuroinflammation induces neurodegeneration</article-title>. <source/>J. Neurol. Neurosurg. Spine
<volume>1</volume>:<fpage>1003</fpage>. <pub-id pub-id-type="pmid">28127589</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Thangavel</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>E.</given-names></name><name><surname>Pattani</surname><given-names>S.</given-names></name><name><surname>Zaheer</surname><given-names>S.</given-names></name><name><surname>Santillan</surname><given-names>D. A.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Dopaminergic toxin 1-methyl-4-phenylpyridinium, proteins α-synuclein and glia maturation factor activate mast cells and release inflammatory mediators</article-title>. <source/>PLoS One
<volume>10</volume>:<fpage>e0135776</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0135776</pub-id><pub-id pub-id-type="pmid">26275153</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M. M.</given-names></name><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Zaheer</surname><given-names>S.</given-names></name><name><surname>Zaheer</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Glia maturation factor deficiency suppresses 1-methyl-4-phenylpyridinium-induced oxidative stress in astrocytes</article-title>. <source/>J. Mol. Neurosci.
<volume>53</volume>, <fpage>590</fpage>–<lpage>599</lpage>. <pub-id pub-id-type="doi">10.1007/s12031-013-0225-z</pub-id><pub-id pub-id-type="pmid">24430624</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>T. K.</given-names></name><name><surname>Alkon</surname><given-names>D. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Peripheral biomarkers of Alzheimer’s disease</article-title>. <source/>J Alzheimers Dis.
<volume>44</volume>, <fpage>729</fpage>–<lpage>744</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-142262</pub-id><pub-id pub-id-type="pmid">25374110</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kielian</surname><given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>Multifaceted roles of neuroinflammation: the need to consider both sides of the coin</article-title>. <source/>J. Neurochem.
<volume>136</volume>, <fpage>5</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13530</pub-id><pub-id pub-id-type="pmid">26806370</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D. Y.</given-names></name><name><surname>Hong</surname><given-names>G. U.</given-names></name><name><surname>Ro</surname><given-names>J. Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40L</article-title>. <source/>J. Neuroinflammation
<volume>8</volume>:<fpage>25</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-8-25</pub-id><pub-id pub-id-type="pmid">21410936</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>W. L.</given-names></name><name><surname>Peng</surname><given-names>Y. Y.</given-names></name><name><surname>Peng</surname><given-names>B. W.</given-names></name></person-group> (<year>2017</year>). <article-title>Modulation of neuroinflammation: role and therapeutic potential of TRPV1 in the neuro-immune axis</article-title>. <source/>Brain Behav. Immun.
<volume>64</volume>, <fpage>354</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2017.03.007</pub-id><pub-id pub-id-type="pmid">28342781</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortekaas</surname><given-names>R.</given-names></name><name><surname>Leenders</surname><given-names>K. L.</given-names></name><name><surname>van Oostrom</surname><given-names>J. C.</given-names></name><name><surname>Vaalburg</surname><given-names>W.</given-names></name><name><surname>Bart</surname><given-names>J.</given-names></name><name><surname>Willemsen</surname><given-names>A. T.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Blood-brain barrier dysfunction in parkinsonian midbrain <italic>in vivo</italic></article-title>. <source/>Ann. Neurol.
<volume>57</volume>, <fpage>176</fpage>–<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1002/ana.20369</pub-id><pub-id pub-id-type="pmid">15668963</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kritas</surname><given-names>S. K.</given-names></name><name><surname>Caraffa</surname><given-names>A.</given-names></name><name><surname>Antinolfi</surname><given-names>P.</given-names></name><name><surname>Saggini</surname><given-names>A.</given-names></name><name><surname>Pantalone</surname><given-names>A.</given-names></name><name><surname>Rosati</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2014a</year>). <article-title>Nerve growth factor interactions with mast cells</article-title>. <source/>Int. J. Immunopathol. Pharmacol.
<volume>27</volume>, <fpage>15</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1177/039463201402700103</pub-id><pub-id pub-id-type="pmid">24674674</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kritas</surname><given-names>S. K.</given-names></name><name><surname>Saggini</surname><given-names>A.</given-names></name><name><surname>Cerulli</surname><given-names>G.</given-names></name><name><surname>Caraffa</surname><given-names>A.</given-names></name><name><surname>Antinolfi</surname><given-names>P.</given-names></name><name><surname>Pantalone</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2014b</year>). <article-title>Corticotropin-releasing hormone, microglia and mental disorders</article-title>. <source/>Int. J. Immunopathol. Pharmacol.
<volume>27</volume>, <fpage>163</fpage>–<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1177/039463201402700203</pub-id><pub-id pub-id-type="pmid">25004828</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulka</surname><given-names>M.</given-names></name><name><surname>Sheen</surname><given-names>C. H.</given-names></name><name><surname>Tancowny</surname><given-names>B. P.</given-names></name><name><surname>Grammer</surname><given-names>L. C.</given-names></name><name><surname>Schleimer</surname><given-names>R. P.</given-names></name></person-group> (<year>2008</year>). <article-title>Neuropeptides activate human mast cell degranulation and chemokine production</article-title>. <source/>Immunology
<volume>123</volume>, <fpage>398</fpage>–<lpage>410</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2567.2007.02705.x</pub-id><pub-id pub-id-type="pmid">17922833</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kure</surname><given-names>C.</given-names></name><name><surname>Timmer</surname><given-names>J.</given-names></name><name><surname>Stough</surname><given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>The immunomodulatory effects of plant extracts and plant secondary metabolites on chronic neuroinflammation and cognitive aging: a mechanistic and empirical review</article-title>. <source/>Front. Pharmacol.
<volume>8</volume>:<fpage>117</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2017.00117</pub-id><pub-id pub-id-type="pmid">28344556</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kvetnoi</surname><given-names>I. M.</given-names></name><name><surname>Kvetnaia</surname><given-names>T. V.</given-names></name><name><surname>Riadnova</surname><given-names>I.</given-names></name><name><surname>Fursov</surname><given-names>B. B.</given-names></name><name><surname>Ernandes-Jago</surname><given-names>H.</given-names></name><name><surname>Blesa</surname><given-names>J. R.</given-names></name></person-group> (<year>2003</year>). <article-title>Expression of β-amyloid and tau-protein in mastocytes in Alzheimer disease</article-title>. <source/>Arkh. Patol.
<volume>65</volume>, <fpage>36</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="pmid">12669611</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labandeira-Garcia</surname><given-names>J. L.</given-names></name><name><surname>Rodriguez-Pallares</surname><given-names>J.</given-names></name><name><surname>Dominguez-Meijide</surname><given-names>A.</given-names></name><name><surname>Valenzuela</surname><given-names>R.</given-names></name><name><surname>Villar-Cheda</surname><given-names>B.</given-names></name><name><surname>Rodriguez-Perez</surname><given-names>A. I.</given-names></name></person-group> (<year>2013</year>). <article-title>Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson’s disease</article-title>. <source/>Mov. Disord.
<volume>28</volume>, <fpage>1337</fpage>–<lpage>1342</lpage>. <pub-id pub-id-type="doi">10.1002/mds.25614</pub-id><pub-id pub-id-type="pmid">23925977</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Neurotransmitters and microglial-mediated neuroinflammation</article-title>. <source/>Curr. Protein Pept. Sci.
<volume>14</volume>, <fpage>21</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.2174/1389203711314010005</pub-id><pub-id pub-id-type="pmid">23441898</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H. J.</given-names></name><name><surname>Suk</surname><given-names>J. E.</given-names></name><name><surname>Patrick</surname><given-names>C.</given-names></name><name><surname>Bae</surname><given-names>E. J.</given-names></name><name><surname>Cho</surname><given-names>J. H.</given-names></name><name><surname>Rho</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Direct transfer of α-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>9262</fpage>–<lpage>9272</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.081125</pub-id><pub-id pub-id-type="pmid">20071342</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehrer</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Nasal NSAIDs for Alzheimer’s disease</article-title>. <source/>Am. J. Alzheimers Dis. Other Demen.
<volume>29</volume>, <fpage>401</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1177/1533317513518658</pub-id><pub-id pub-id-type="pmid">24413537</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W. W.</given-names></name><name><surname>Guo</surname><given-names>T. Z.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>T.</given-names></name><name><surname>Clark</surname><given-names>D. J.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Substance P spinal signaling induces glial activation and nociceptive sensitization after fracture</article-title>. <source/>Neuroscience
<volume>310</volume>, <fpage>73</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.09.036</pub-id><pub-id pub-id-type="pmid">26386297</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Chang</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Overexpression of SIRT1 induced by resveratrol and inhibitor of miR-204 suppresses activation and proliferation of microglia</article-title>. <source/>J. Mol. Neurosci.
<volume>56</volume>, <fpage>858</fpage>–<lpage>867</lpage>. <pub-id pub-id-type="doi">10.1007/s12031-015-0526-5</pub-id><pub-id pub-id-type="pmid">25725784</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y. L.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Cheng</surname><given-names>X. D.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>C. Y.</given-names></name><name><surname>Lü</surname><given-names>W. G.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Identification of glia maturation factor β as an independent prognostic predictor for serous ovarian cancer</article-title>. <source/>Eur. J. Cancer
<volume>46</volume>, <fpage>2104</fpage>–<lpage>2118</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2010.04.015</pub-id><pub-id pub-id-type="pmid">20547056</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Dong</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Bidirectional relationship of mast cells-neurovascular unit communication in neuroinflammation and its involvement in POCD</article-title>. <source/>Behav. Brain Res.
<volume>322</volume>, <fpage>60</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2017.01.006</pub-id><pub-id pub-id-type="pmid">28082194</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>Y. X.</given-names></name><name><surname>Zaheer</surname><given-names>A.</given-names></name></person-group> (<year>1990a</year>). <article-title>Cell-surface expression of glia maturation factor β in astrocytes</article-title>. <source/>FASEB J.
<volume>4</volume>, <fpage>3360</fpage>–<lpage>3363</lpage>. <pub-id pub-id-type="pmid">2253851</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>R.</given-names></name><name><surname>Zaheer</surname><given-names>A.</given-names></name><name><surname>Lane</surname><given-names>W. S.</given-names></name></person-group> (<year>1990b</year>). <article-title>Complete amino acid sequence of bovine glia maturation factor β</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>87</volume>, <fpage>5233</fpage>–<lpage>5237</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.87.14.5233</pub-id><pub-id pub-id-type="pmid">2196564</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>R.</given-names></name><name><surname>Miller</surname><given-names>J. F.</given-names></name><name><surname>Zaheer</surname><given-names>A.</given-names></name></person-group> (<year>1989</year>). <article-title>Purification and characterization of glia maturation factor β: a growth regulator for neurons and glia</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>86</volume>, <fpage>3901</fpage>–<lpage>3905</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.86.10.3901</pub-id><pub-id pub-id-type="pmid">2726756</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litteljohn</surname><given-names>D.</given-names></name><name><surname>Hayley</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Cytokines as potential biomarkers for Parkinson’s disease: a multiplex approach</article-title>. <source/>Methods Mol. Biol.
<volume>934</volume>, <fpage>121</fpage>–<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-62703-071-7_7</pub-id><pub-id pub-id-type="pmid">22933144</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litteljohn</surname><given-names>D.</given-names></name><name><surname>Mangano</surname><given-names>E.</given-names></name><name><surname>Clarke</surname><given-names>M.</given-names></name><name><surname>Bobyn</surname><given-names>J.</given-names></name><name><surname>Moloney</surname><given-names>K.</given-names></name><name><surname>Hayley</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson’s disease</article-title>. <source/>Parkinsons Dis.
<volume>2011</volume>:<fpage>713517</fpage>. <pub-id pub-id-type="doi">10.4061/2011/713517</pub-id><pub-id pub-id-type="pmid">21234362</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>S. M.</given-names></name><name><surname>Rothwell</surname><given-names>N. J.</given-names></name><name><surname>Gibson</surname><given-names>R. M.</given-names></name></person-group> (<year>2006</year>). <article-title>The role of inflammation in CNS injury and disease</article-title>. <source/>Br. J. Pharmacol.
<volume>147</volume>, <fpage>S232</fpage>–<lpage>S240</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0706400</pub-id><pub-id pub-id-type="pmid">16402109</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>A.</given-names></name><name><surname>Herrera</surname><given-names>A. J.</given-names></name><name><surname>Venero</surname><given-names>J. L.</given-names></name><name><surname>Santiago</surname><given-names>M.</given-names></name><name><surname>De Pablos</surname><given-names>R. M.</given-names></name><name><surname>Villaran</surname><given-names>R. F.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson’s disease incidence</article-title>. <source/>Parkinsons Dis.
<volume>2011</volume>:<fpage>393769</fpage>. <pub-id pub-id-type="doi">10.4061/2011/393769</pub-id><pub-id pub-id-type="pmid">21603178</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcello</surname><given-names>E.</given-names></name><name><surname>Gardoni</surname><given-names>F.</given-names></name><name><surname>Di Luca</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Alzheimer’s disease and modern lifestyle: what is the role of stress?</article-title>
<source/>J. Neurochem.
<volume>134</volume>, <fpage>795</fpage>–<lpage>798</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13210</pub-id><pub-id pub-id-type="pmid">26206000</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCusker</surname><given-names>R. H.</given-names></name><name><surname>Kelley</surname><given-names>K. W.</given-names></name></person-group> (<year>2013</year>). <article-title>Immune-neural connections: how the immune system’s response to infectious agents influences behavior</article-title>. <source/>J. Exp. Biol.
<volume>216</volume>, <fpage>84</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1242/jeb.073411</pub-id><pub-id pub-id-type="pmid">23225871</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenzie</surname><given-names>J. A.</given-names></name><name><surname>Spielman</surname><given-names>L. J.</given-names></name><name><surname>Pointer</surname><given-names>C. B.</given-names></name><name><surname>Lowry</surname><given-names>J. R.</given-names></name><name><surname>Bajwa</surname><given-names>E.</given-names></name><name><surname>Lee</surname><given-names>C. W.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Neuroinflammation as a common mechanism associated with the modifiable risk factors for Alzheimer’s and Parkinson’s diseases</article-title>. <source/>Curr. Aging Sci. [Epub ahead of print]. <pub-id pub-id-type="doi">10.2174/1874609810666170315113244</pub-id><pub-id pub-id-type="pmid">28302047</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McManus</surname><given-names>R. M.</given-names></name><name><surname>Heneka</surname><given-names>M. T.</given-names></name></person-group> (<year>2017</year>). <article-title>Role of neuroinflammation in neurodegeneration: new insights</article-title>. <source/>Alzheimers Res. Ther.
<volume>9</volume>:<fpage>14</fpage>. <pub-id pub-id-type="doi">10.1186/s13195-017-0241-2</pub-id><pub-id pub-id-type="pmid">28259169</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mekori</surname><given-names>Y. A.</given-names></name><name><surname>Metcalfe</surname><given-names>D. D.</given-names></name></person-group> (<year>2000</year>). <article-title>Mast cells in innate immunity</article-title>. <source/>Immunol. Rev.
<volume>173</volume>, <fpage>131</fpage>–<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1034/j.1600-065X.2000.917305.x</pub-id><pub-id pub-id-type="pmid">10719674</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metz</surname><given-names>M.</given-names></name><name><surname>Grimbaldeston</surname><given-names>M. A.</given-names></name><name><surname>Nakae</surname><given-names>S.</given-names></name><name><surname>Piliponsky</surname><given-names>A. M.</given-names></name><name><surname>Tsai</surname><given-names>M.</given-names></name><name><surname>Galli</surname><given-names>S. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Mast cells in the promotion and limitation of chronic inflammation</article-title>. <source/>Immunol. Rev.
<volume>217</volume>, <fpage>304</fpage>–<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-065x.2007.00520.x</pub-id><pub-id pub-id-type="pmid">17498068</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>More</surname><given-names>S. V.</given-names></name><name><surname>Kumar</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>I. S.</given-names></name><name><surname>Song</surname><given-names>S. Y.</given-names></name><name><surname>Choi</surname><given-names>D. K.</given-names></name></person-group> (<year>2013</year>). <article-title>Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson’s disease</article-title>. <source/>Mediators Inflamm.
<volume>2013</volume>:<fpage>952375</fpage>. <pub-id pub-id-type="doi">10.1155/2013/952375</pub-id><pub-id pub-id-type="pmid">23935251</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>T.</given-names></name><name><surname>Kabashima</surname><given-names>K.</given-names></name><name><surname>Fukamachi</surname><given-names>S.</given-names></name><name><surname>Kuroda</surname><given-names>E.</given-names></name><name><surname>Sakabe</surname><given-names>J.</given-names></name><name><surname>Kobayashi</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>D1-like dopamine receptors antagonist inhibits cutaneous immune reactions mediated by Th2 and mast cells</article-title>. <source/>J. Dermatol. Sci.
<volume>71</volume>, <fpage>37</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.jdermsci.2013.03.008</pub-id><pub-id pub-id-type="pmid">23639699</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>H.</given-names></name><name><surname>Saito</surname><given-names>H.</given-names></name><name><surname>Matsumoto</surname><given-names>K.</given-names></name><name><surname>Nakae</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Regulatory roles of mast cells in immune responses</article-title>. <source/>Semin Immunopathol.
<volume>38</volume>, <fpage>623</fpage>–<lpage>629</lpage>. <pub-id pub-id-type="doi">10.1007/s00281-016-0566-0</pub-id><pub-id pub-id-type="pmid">27154294</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullin</surname><given-names>S.</given-names></name><name><surname>Schapira</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>α-Synuclein and mitochondrial dysfunction in Parkinson’s disease</article-title>. <source/>Mol. Neurobiol.
<volume>47</volume>, <fpage>587</fpage>–<lpage>597</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-013-8394-x</pub-id><pub-id pub-id-type="pmid">23361255</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negre-Salvayre</surname><given-names>A.</given-names></name><name><surname>Hirtz</surname><given-names>C.</given-names></name><name><surname>Carrera</surname><given-names>G.</given-names></name><name><surname>Cazenave</surname><given-names>R.</given-names></name><name><surname>Troly</surname><given-names>M.</given-names></name><name><surname>Salvayre</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>1997</year>). <article-title>A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation</article-title>. <source/>FASEB J.
<volume>11</volume>, <fpage>809</fpage>–<lpage>815</lpage>. <pub-id pub-id-type="pmid">9271366</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelissen</surname><given-names>S.</given-names></name><name><surname>Lemmens</surname><given-names>E.</given-names></name><name><surname>Geurts</surname><given-names>N.</given-names></name><name><surname>Kramer</surname><given-names>P.</given-names></name><name><surname>Maurer</surname><given-names>M.</given-names></name><name><surname>Hendriks</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>The role of mast cells in neuroinflammation</article-title>. <source/>Acta Neuropathol.
<volume>125</volume>, <fpage>637</fpage>–<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-013-1092-y</pub-id><pub-id pub-id-type="pmid">23404369</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoletti</surname><given-names>M.</given-names></name><name><surname>Neri</surname><given-names>G.</given-names></name><name><surname>Maccauro</surname><given-names>G.</given-names></name><name><surname>Tripodi</surname><given-names>D.</given-names></name><name><surname>Varvara</surname><given-names>G.</given-names></name><name><surname>Saggini</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Impact of neuropeptide substance P an inflammatory compound on arachidonic acid compound generation</article-title>. <source/>Int. J. Immunopathol. Pharmacol.
<volume>25</volume>, <fpage>849</fpage>–<lpage>857</lpage>. <pub-id pub-id-type="doi">10.1177/039463201202500403</pub-id><pub-id pub-id-type="pmid">23298476</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niederhoffer</surname><given-names>N.</given-names></name><name><surname>Levy</surname><given-names>R.</given-names></name><name><surname>Sick</surname><given-names>E.</given-names></name><name><surname>Andre</surname><given-names>P.</given-names></name><name><surname>Coupin</surname><given-names>G.</given-names></name><name><surname>Lombard</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Amyloid β peptides trigger CD47-dependent mast cell secretory and phagocytic responses</article-title>. <source/>Int. J. Immunopathol. Pharmacol.
<volume>22</volume>, <fpage>473</fpage>–<lpage>483</lpage>. <pub-id pub-id-type="doi">10.1177/039463200902200224</pub-id><pub-id pub-id-type="pmid">19505377</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nobili</surname><given-names>A.</given-names></name><name><surname>Latagliata</surname><given-names>E. C.</given-names></name><name><surname>Viscomi</surname><given-names>M. T.</given-names></name><name><surname>Cavallucci</surname><given-names>V.</given-names></name><name><surname>Cutuli</surname><given-names>D.</given-names></name><name><surname>Giacovazzo</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer’s disease</article-title>. <source/>Nat. Commun.
<volume>8</volume>:<fpage>14727</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms14727</pub-id><pub-id pub-id-type="pmid">28367951</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Normoyle</surname><given-names>K. P.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Farahvar</surname><given-names>A.</given-names></name><name><surname>Llano</surname><given-names>D.</given-names></name><name><surname>Jackson</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group> (<year>2015</year>). <article-title>The emerging neuroprotective role of mitochondrial uncoupling protein-2 in traumatic brain injury</article-title>. <source/>Transl. Neurosci.
<volume>6</volume>, <fpage>179</fpage>–<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1515/tnsci-2015-0019</pub-id><pub-id pub-id-type="pmid">28123803</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ock</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>W. H.</given-names></name><name><surname>Choi</surname><given-names>D. K.</given-names></name><name><surname>Park</surname><given-names>E. J.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Induction of microglial apoptosis by corticotropin-releasing hormone</article-title>. <source/>J. Neurochem.
<volume>98</volume>, <fpage>962</fpage>–<lpage>972</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03933.x</pub-id><pub-id pub-id-type="pmid">16893426</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulou</surname><given-names>N. G.</given-names></name><name><surname>Oleson</surname><given-names>L.</given-names></name><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Donelan</surname><given-names>J.</given-names></name><name><surname>Cetrulo</surname><given-names>C. L.</given-names></name><name><surname>Theoharides</surname><given-names>T. C.</given-names></name></person-group> (<year>2005</year>). <article-title>Regulation of corticotropin-releasing hormone receptor-2 expression in human cord blood-derived cultured mast cells</article-title>. <source/>J. Mol. Endocrinol.
<volume>35</volume>, <fpage>R1</fpage>–<lpage>R8</lpage>. <pub-id pub-id-type="doi">10.1677/jme.1.01833</pub-id><pub-id pub-id-type="pmid">16326828</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardon</surname><given-names>M. C.</given-names></name></person-group> (<year>2011</year>). <article-title>Therapeutic potential of some stress mediators in early Alzheimer’s disease</article-title>. <source/>Exp. Gerontol.
<volume>46</volume>, <fpage>170</fpage>–<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2010.09.006</pub-id><pub-id pub-id-type="pmid">20870017</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H. S.</given-names></name><name><surname>Park</surname><given-names>M. J.</given-names></name><name><surname>Kwon</surname><given-names>M. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Central nervous system-peripheral immune system dialogue in neurological disorders: possible application of neuroimmunology in urology</article-title>. <source/>Int. Neurourol. J.
<volume>20</volume>, <fpage>S8</fpage>–<lpage>S14</lpage>. <pub-id pub-id-type="doi">10.5213/inj.1632614.307</pub-id><pub-id pub-id-type="pmid">27230462</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peixoto</surname><given-names>P. M.</given-names></name><name><surname>Kim</surname><given-names>H. J.</given-names></name><name><surname>Sider</surname><given-names>B.</given-names></name><name><surname>Starkov</surname><given-names>A.</given-names></name><name><surname>Horvath</surname><given-names>T. L.</given-names></name><name><surname>Manfredi</surname><given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>UCP2 overexpression worsens mitochondrial dysfunction and accelerates disease progression in a mouse model of amyotrophic lateral sclerosis</article-title>. <source/>Mol. Cell. Neurosci.
<volume>57</volume>, <fpage>104</fpage>–<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1016/j.mcn.2013.10.002</pub-id><pub-id pub-id-type="pmid">24141050</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennisi</surname><given-names>M.</given-names></name><name><surname>Crupi</surname><given-names>R.</given-names></name><name><surname>Di Paola</surname><given-names>R.</given-names></name><name><surname>Ontario</surname><given-names>M. L.</given-names></name><name><surname>Bella</surname><given-names>R.</given-names></name><name><surname>Calabrese</surname><given-names>E. J.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Inflammasomes, hormesis and antioxidants in neuroinflammation: role of NRLP3 in Alzheimer disease</article-title>. <source/>J. Neurosci. Res.
<volume>95</volume>, <fpage>1360</fpage>–<lpage>1372</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.23986</pub-id><pub-id pub-id-type="pmid">27862176</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>V. H.</given-names></name></person-group> (<year>2004</year>). <article-title>The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease</article-title>. <source/>Brain Behav. Immun.
<volume>18</volume>, <fpage>407</fpage>–<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2004.01.004</pub-id><pub-id pub-id-type="pmid">15265532</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>V. H.</given-names></name></person-group> (<year>2010</year>). <article-title>Contribution of systemic inflammation to chronic neurodegeneration</article-title>. <source/>Acta Neuropathol.
<volume>120</volume>, <fpage>277</fpage>–<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-010-0722-x</pub-id><pub-id pub-id-type="pmid">20644946</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>V. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Microglia</article-title>. <source/>Microbiol. Spectr.
<volume>4</volume>. <pub-id pub-id-type="doi">10.1128/microbiolspec.MCHD-0003-2015</pub-id><pub-id pub-id-type="pmid">27337461</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>V. H.</given-names></name><name><surname>Cunningham</surname><given-names>C.</given-names></name><name><surname>Holmes</surname><given-names>C.</given-names></name></person-group> (<year>2007</year>). <article-title>Systemic infections and inflammation affect chronic neurodegeneration</article-title>. <source/>Nat. Rev. Immunol.
<volume>7</volume>, <fpage>161</fpage>–<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1038/nri2015</pub-id><pub-id pub-id-type="pmid">17220915</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>V. H.</given-names></name><name><surname>Nicoll</surname><given-names>J. A.</given-names></name><name><surname>Holmes</surname><given-names>C.</given-names></name></person-group> (<year>2010</year>). <article-title>Microglia in neurodegenerative disease</article-title>. <source/>Nat. Rev. Neurol.
<volume>6</volume>, <fpage>193</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2010.17</pub-id><pub-id pub-id-type="pmid">20234358</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prinz</surname><given-names>M.</given-names></name><name><surname>Priller</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>The role of peripheral immune cells in the CNS in steady state and disease</article-title>. <source/>Nat. Neurosci.
<volume>20</volume>, <fpage>136</fpage>–<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4475</pub-id><pub-id pub-id-type="pmid">28092660</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Block</surname><given-names>M. L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Breese</surname><given-names>G. R.</given-names></name><name><surname>Hong</surname><given-names>J. S.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration</article-title>. <source/>Glia
<volume>55</volume>, <fpage>453</fpage>–<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1002/glia.20467</pub-id><pub-id pub-id-type="pmid">17203472</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsden</surname><given-names>D. B.</given-names></name><name><surname>Ho</surname><given-names>P. W.</given-names></name><name><surname>Ho</surname><given-names>J. W.</given-names></name><name><surname>Liu</surname><given-names>H. F.</given-names></name><name><surname>So</surname><given-names>D. H.</given-names></name><name><surname>Tse</surname><given-names>H. M.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Human neuronal uncoupling proteins 4 and 5 (UCP4 and UCP5): structural properties, regulation and physiological role in protection against oxidative stress and mitochondrial dysfunction</article-title>. <source/>Brain Behav.
<volume>2</volume>, <fpage>468</fpage>–<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1002/brb3.55</pub-id><pub-id pub-id-type="pmid">22950050</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ransohoff</surname><given-names>R. M.</given-names></name><name><surname>Brown</surname><given-names>M. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Innate immunity in the central nervous system</article-title>. <source/>J. Clin. Invest.
<volume>122</volume>, <fpage>1164</fpage>–<lpage>1171</lpage>. <pub-id pub-id-type="doi">10.1172/JCI58644</pub-id><pub-id pub-id-type="pmid">22466658</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ransohoff</surname><given-names>R. M.</given-names></name><name><surname>Kivisäkk</surname><given-names>P.</given-names></name><name><surname>Kidd</surname><given-names>G.</given-names></name></person-group> (<year>2003</year>). <article-title>Three or more routes for leukocyte migration into the central nervous system</article-title>. <source/>Curr. Opin. Immunol.
<volume>3</volume>, <fpage>569</fpage>–<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1038/nri1130</pub-id><pub-id pub-id-type="pmid">17010588</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronnberg</surname><given-names>E.</given-names></name><name><surname>Calounova</surname><given-names>G.</given-names></name><name><surname>Pejler</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Mast cells express tyrosine hydroxylase and store dopamine in a serglycin-dependent manner</article-title>. <source/>Biol. Chem.
<volume>393</volume>, <fpage>107</fpage>–<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1515/BC-2011-220</pub-id><pub-id pub-id-type="pmid">22628305</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousset</surname><given-names>S.</given-names></name><name><surname>Emre</surname><given-names>Y.</given-names></name><name><surname>Join-Lambert</surname><given-names>O.</given-names></name><name><surname>Hurtaud</surname><given-names>C.</given-names></name><name><surname>Ricquier</surname><given-names>D.</given-names></name><name><surname>Cassard-Doulcier</surname><given-names>A. M.</given-names></name></person-group> (<year>2006</year>). <article-title>The uncoupling protein 2 modulates the cytokine balance in innate immunity</article-title>. <source/>Cytokine
<volume>35</volume>, <fpage>135</fpage>–<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2006.07.012</pub-id><pub-id pub-id-type="pmid">16971137</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russi</surname><given-names>A. E.</given-names></name><name><surname>Walker-Caulfield</surname><given-names>M. E.</given-names></name><name><surname>Brown</surname><given-names>M. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Mast cell inflammasome activity in the meninges regulates EAE disease severity</article-title>. <source/>Clin. Immunol. [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.clim.2016.04.009</pub-id><pub-id pub-id-type="pmid">27108197</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rustenhoven</surname><given-names>J.</given-names></name><name><surname>Jansson</surname><given-names>D.</given-names></name><name><surname>Smyth</surname><given-names>L. C.</given-names></name><name><surname>Dragunow</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Brain pericytes as mediators of neuroinflammation</article-title>. <source/>Trends Pharmacol. Sci.
<volume>38</volume>, <fpage>291</fpage>–<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2016.12.001</pub-id><pub-id pub-id-type="pmid">28017362</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>J. J.</given-names></name><name><surname>Morales</surname><given-names>J. K.</given-names></name><name><surname>Falanga</surname><given-names>Y. T.</given-names></name><name><surname>Fernando</surname><given-names>J. F.</given-names></name><name><surname>Macey</surname><given-names>M. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Mast cell regulation of the immune response</article-title>. <source/>World Allergy Organ. J.
<volume>2</volume>, <fpage>224</fpage>–<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1097/WOX.0b013e3181c2a95e</pub-id><pub-id pub-id-type="pmid">23283207</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>J. W.</given-names></name><name><surname>Hong</surname><given-names>K. H.</given-names></name><name><surname>Maeng</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>J. B.</given-names></name><name><surname>Ko</surname><given-names>J.</given-names></name><name><surname>Park</surname><given-names>J. Y.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Overexpression of uncoupling protein 2 in THP1 monocytes inhibits β2 integrin-mediated firm adhesion and transendothelial migration</article-title>. <source/>Arterioscler Thromb Vasc. Biol.
<volume>24</volume>, <fpage>864</fpage>–<lpage>870</lpage>. <pub-id pub-id-type="doi">10.1161/01.ATV.0000125705.28058.eb</pub-id><pub-id pub-id-type="pmid">15016641</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>H.</given-names></name></person-group> (<year>2014</year>). <article-title>Mast cell research</article-title>. <source/>Chem. Immunol. Allergy
<volume>100</volume>, <fpage>165</fpage>–<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1159/000358733</pub-id><pub-id pub-id-type="pmid">24925397</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>T.</given-names></name><name><surname>Bunnett</surname><given-names>N. W.</given-names></name></person-group> (<year>2005</year>). <article-title>Protease-activated receptors: regulation of neuronal function</article-title>. <source/>Neuromolecular Med.
<volume>7</volume>, <fpage>79</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1385/nmm:7:1-2:079</pub-id><pub-id pub-id-type="pmid">16052040</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawikr</surname><given-names>Y.</given-names></name><name><surname>Yarla</surname><given-names>N. S.</given-names></name><name><surname>Peluso</surname><given-names>I.</given-names></name><name><surname>Kamal</surname><given-names>M. A.</given-names></name><name><surname>Aliev</surname><given-names>G.</given-names></name><name><surname>Bishayee</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Neuroinflammation in Alzheimer’s disease: the preventive and therapeutic potential of polyphenolic nutraceuticals</article-title>. <source/>Adv. Protein Chem. Struct. Biol.
<volume>108</volume>, <fpage>33</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/bs.apcsb.2017.02.001</pub-id><pub-id pub-id-type="pmid">28427563</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayed</surname><given-names>B. A.</given-names></name><name><surname>Walker</surname><given-names>M. E.</given-names></name><name><surname>Brown</surname><given-names>M. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Cutting edge: mast cells regulate disease severity in a relapsing-remitting model of multiple sclerosis</article-title>. <source/>J. Immunol.
<volume>186</volume>, <fpage>3294</fpage>–<lpage>3298</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1003574</pub-id><pub-id pub-id-type="pmid">21325623</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schain</surname><given-names>M.</given-names></name><name><surname>Kreisl</surname><given-names>W. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Neuroinflammation in neurodegenerative disorders-a review</article-title>. <source/>Curr. Neurol. Neurosci. Rep.
<volume>17</volume>:<fpage>25</fpage>. <pub-id pub-id-type="doi">10.1007/s11910-017-0733-2</pub-id><pub-id pub-id-type="pmid">28283959</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>L. B.</given-names></name></person-group> (<year>2002</year>). <article-title>Mast cells and basophils</article-title>. <source/>Clin. Allergy Immunol.
<volume>16</volume>, <fpage>3</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="pmid">11577545</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Secor</surname><given-names>V. H.</given-names></name><name><surname>Secor</surname><given-names>W. E.</given-names></name><name><surname>Gutekunst</surname><given-names>C. A.</given-names></name><name><surname>Brown</surname><given-names>M. A.</given-names></name></person-group> (<year>2000</year>). <article-title>Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis</article-title>. <source/>J. Exp. Med.
<volume>191</volume>, <fpage>813</fpage>–<lpage>822</lpage>. <pub-id pub-id-type="doi">10.1084/jem.191.5.813</pub-id><pub-id pub-id-type="pmid">10704463</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segura-Aguilar</surname><given-names>J.</given-names></name><name><surname>Paris</surname><given-names>I.</given-names></name><name><surname>Muñoz</surname><given-names>P.</given-names></name><name><surname>Ferrari</surname><given-names>E.</given-names></name><name><surname>Zecca</surname><given-names>L.</given-names></name><name><surname>Zucca</surname><given-names>F. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Protective and toxic roles of dopamine in Parkinson’s disease</article-title>. <source/>J. Neurochem.
<volume>129</volume>, <fpage>898</fpage>–<lpage>915</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.12686</pub-id><pub-id pub-id-type="pmid">24548101</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Severini</surname><given-names>C.</given-names></name><name><surname>Petrella</surname><given-names>C.</given-names></name><name><surname>Calissano</surname><given-names>P.</given-names></name></person-group> (<year>2016</year>). <article-title>Substance P and Alzheimer’s disease: emerging novel roles</article-title>. <source/>Curr. Alzheimer Res.
<volume>13</volume>, <fpage>964</fpage>–<lpage>972</lpage>. <pub-id pub-id-type="doi">10.2174/1567205013666160401114039</pub-id><pub-id pub-id-type="pmid">27033058</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaik-Dasthagirisaheb</surname><given-names>Y. B.</given-names></name><name><surname>Varvara</surname><given-names>G.</given-names></name><name><surname>Murmura</surname><given-names>G.</given-names></name><name><surname>Saggini</surname><given-names>A.</given-names></name><name><surname>Potalivo</surname><given-names>G.</given-names></name><name><surname>Caraffa</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Vascular endothelial growth factor (VEGF), mast cells and inflammation</article-title>. <source/>Int. J. Immunopathol. Pharmacol.
<volume>26</volume>, <fpage>327</fpage>–<lpage>335</lpage>. <pub-id pub-id-type="doi">10.1177/039463201302600206</pub-id><pub-id pub-id-type="pmid">23755748</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalit</surname><given-names>F.</given-names></name><name><surname>Sredni</surname><given-names>B.</given-names></name><name><surname>Brodie</surname><given-names>C.</given-names></name><name><surname>Kott</surname><given-names>E.</given-names></name><name><surname>Huberman</surname><given-names>M.</given-names></name></person-group> (<year>1995</year>). <article-title>T lymphocyte subpopulations and activation markers correlate with severity of Alzheimer’s disease</article-title>. <source/>Clin. Immunol. Immunopathol.
<volume>75</volume>, <fpage>246</fpage>–<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1006/clin.1995.1078</pub-id><pub-id pub-id-type="pmid">7768042</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Cook</surname><given-names>T. J.</given-names></name><name><surname>Bullock</surname><given-names>K. M.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Ginghina</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease</article-title>. <source/>Acta Neuropathol.
<volume>128</volume>, <fpage>639</fpage>–<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-014-1314-y</pub-id><pub-id pub-id-type="pmid">24997849</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>X.</given-names></name><name><surname>Pu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>Structure, distribution, and genetic profile of α-synuclein and their potential clinical application in Parkinson’s disease</article-title>. <source/>J. Mov. Disord.
<volume>10</volume>, <fpage>69</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.14802/jmd.16061</pub-id><pub-id pub-id-type="pmid">28479587</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>R.</given-names></name><name><surname>Curley</surname><given-names>J. P.</given-names></name></person-group> (<year>2013</year>). <article-title>Mast cells on the mind: new insights and opportunities</article-title>. <source/>Trends Neurosci.
<volume>36</volume>, <fpage>513</fpage>–<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2013.06.001</pub-id><pub-id pub-id-type="pmid">23845731</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>M. R.</given-names></name><name><surname>Margulis</surname><given-names>A.</given-names></name><name><surname>Wood</surname><given-names>N.</given-names></name><name><surname>Goldman</surname><given-names>S. J.</given-names></name><name><surname>Kasaian</surname><given-names>M.</given-names></name><name><surname>Chaudhary</surname><given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation</article-title>. <source/>Inflamm. Res.
<volume>59</volume>, <fpage>207</fpage>–<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1007/s00011-009-0088-5</pub-id><pub-id pub-id-type="pmid">19763788</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>A. J.</given-names></name><name><surname>Sutherland</surname><given-names>A. K.</given-names></name><name><surname>Wilhelm</surname><given-names>M.</given-names></name><name><surname>Silver</surname><given-names>R.</given-names></name></person-group> (<year>2000</year>). <article-title>Mast cells migrate from blood to brain</article-title>. <source/>J. Neurosci.
<volume>20</volume>, <fpage>401</fpage>–<lpage>408</lpage>. <pub-id pub-id-type="pmid">10627616</pub-id></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sismanopoulos</surname><given-names>N.</given-names></name><name><surname>Delivanis</surname><given-names>D. A.</given-names></name><name><surname>Alysandratos</surname><given-names>K. D.</given-names></name><name><surname>Angelidou</surname><given-names>A.</given-names></name><name><surname>Therianou</surname><given-names>A.</given-names></name><name><surname>Kalogeromitros</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Mast cells in allergic and inflammatory diseases</article-title>. <source/>Curr. Pharm. Des.
<volume>18</volume>, <fpage>2261</fpage>–<lpage>2277</lpage>. <pub-id pub-id-type="doi">10.2174/138161212800165997</pub-id><pub-id pub-id-type="pmid">22390690</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skaper</surname><given-names>S. D.</given-names></name></person-group> (<year>2016</year>). <article-title>Mast cell - glia dialogue in chronic pain and neuropathic pain: blood-brain barrier implications</article-title>. <source/>CNS Neurol. Disord. Drug Targets
<volume>15</volume>, <fpage>1072</fpage>–<lpage>1078</lpage>. <pub-id pub-id-type="doi">10.2174/1871527315666160829105533</pub-id><pub-id pub-id-type="pmid">27573801</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skaper</surname><given-names>S. D.</given-names></name><name><surname>Facci</surname><given-names>L.</given-names></name></person-group> (<year>2012</year>). <article-title>Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide</article-title>. <source/>Philos. Trans. R. Soc. Lond. B Biol. Sci.
<volume>367</volume>, <fpage>3312</fpage>–<lpage>3325</lpage>. <pub-id pub-id-type="doi">10.1098/rstb.2011.0391</pub-id><pub-id pub-id-type="pmid">23108549</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skaper</surname><given-names>S. D.</given-names></name><name><surname>Facci</surname><given-names>L.</given-names></name><name><surname>Giusti</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator</article-title>. <source/>Mol. Neurobiol.
<volume>48</volume>, <fpage>340</fpage>–<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-013-8487-6</pub-id><pub-id pub-id-type="pmid">23813098</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skaper</surname><given-names>S. D.</given-names></name><name><surname>Facci</surname><given-names>L.</given-names></name><name><surname>Giusti</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Mast cells, glia and neuroinflammation: partners in crime?</article-title>
<source/>Immunology
<volume>141</volume>, <fpage>314</fpage>–<lpage>327</lpage>. <pub-id pub-id-type="doi">10.1111/imm.12170</pub-id><pub-id pub-id-type="pmid">24032675</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skaper</surname><given-names>S. D.</given-names></name><name><surname>Giusti</surname><given-names>P.</given-names></name><name><surname>Facci</surname><given-names>L.</given-names></name></person-group> (<year>2012</year>). <article-title>Microglia and mast cells: two tracks on the road to neuroinflammation</article-title>. <source/>FASEB J.
<volume>26</volume>, <fpage>3103</fpage>–<lpage>3117</lpage>. <pub-id pub-id-type="doi">10.1096/fj.11-197194</pub-id><pub-id pub-id-type="pmid">22516295</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Pei</surname><given-names>L.</given-names></name><name><surname>Yao</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Shang</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>NLRP3 inflammasome in neurological diseases, from functions to therapies</article-title>. <source/>Front. Cell. Neurosci.
<volume>11</volume>:<fpage>63</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2017.00063</pub-id><pub-id pub-id-type="pmid">28337127</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stolmeier</surname><given-names>D.</given-names></name><name><surname>Thangavel</surname><given-names>R.</given-names></name><name><surname>Anantharam</surname><given-names>P.</given-names></name><name><surname>Khan</surname><given-names>M. M.</given-names></name><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Zaheer</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Glia maturation factor expression in hippocampus of human Alzheimer’s disease</article-title>. <source/>Neurochem. Res.
<volume>38</volume>, <fpage>1580</fpage>–<lpage>1589</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-013-1059-3</pub-id><pub-id pub-id-type="pmid">23640177</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>Y. T.</given-names></name><name><surname>Bullock</surname><given-names>K. M.</given-names></name><name><surname>Erickson</surname><given-names>M. A.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Banks</surname><given-names>W. A.</given-names></name></person-group> (<year>2014</year>). <article-title>α synuclein is transported into and out of the brain by the blood-brain barrier</article-title>. <source/>Peptides
<volume>62</volume>, <fpage>197</fpage>–<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2014.09.018</pub-id><pub-id pub-id-type="pmid">25278492</pub-id></mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y. X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Shelburne</surname><given-names>C. E.</given-names></name><name><surname>Lopatin</surname><given-names>D. E.</given-names></name><name><surname>Chinnaiyan</surname><given-names>A. M.</given-names></name><name><surname>Rubin</surname><given-names>M. A.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) <italic>in vivo</italic></article-title>. <source/>J. Cell. Biochem.
<volume>89</volume>, <fpage>462</fpage>–<lpage>473</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.10522</pub-id><pub-id pub-id-type="pmid">12761880</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szekely</surname><given-names>C. A.</given-names></name><name><surname>Zandi</surname><given-names>P. P.</given-names></name></person-group> (<year>2010</year>). <article-title>Non-steroidal anti-inflammatory drugs and Alzheimer’s disease: the epidemiological evidence</article-title>. <source/>CNS Neurol. Disord. Drug Targets
<volume>9</volume>, <fpage>132</fpage>–<lpage>139</lpage>. <pub-id pub-id-type="doi">10.2174/187152710791012026</pub-id><pub-id pub-id-type="pmid">20205647</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagen</surname><given-names>M.</given-names></name><name><surname>Elorza</surname><given-names>A.</given-names></name><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Boucher</surname><given-names>W.</given-names></name><name><surname>Kepley</surname><given-names>C. L.</given-names></name><name><surname>Shirihai</surname><given-names>O. S.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Mitochondrial uncoupling protein 2 inhibits mast cell activation and reduces histamine content</article-title>. <source/>J. Immunol.
<volume>183</volume>, <fpage>6313</fpage>–<lpage>6319</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0803422</pub-id><pub-id pub-id-type="pmid">19846869</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>S.</given-names></name><name><surname>Sato</surname><given-names>N.</given-names></name><name><surname>Ikimura</surname><given-names>K.</given-names></name><name><surname>Nishino</surname><given-names>H.</given-names></name><name><surname>Rakugi</surname><given-names>H.</given-names></name><name><surname>Morishita</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>Increased blood-brain barrier vulnerability to systemic inflammation in an Alzheimer disease mouse model</article-title>. <source/>Neurobiol. Aging
<volume>34</volume>, <fpage>2064</fpage>–<lpage>2070</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.02.010</pub-id><pub-id pub-id-type="pmid">23561508</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>S.</given-names></name><name><surname>Sato</surname><given-names>N.</given-names></name><name><surname>Morishita</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy</article-title>. <source/>Front. Aging Neurosci.
<volume>6</volume>:<fpage>171</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2014.00171</pub-id><pub-id pub-id-type="pmid">25120476</pub-id></mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanzola</surname><given-names>M. B.</given-names></name><name><surname>Robbie-Ryan</surname><given-names>M.</given-names></name><name><surname>Gutekunst</surname><given-names>C. A.</given-names></name><name><surname>Brown</surname><given-names>M. A.</given-names></name></person-group> (<year>2003</year>). <article-title>Mast cells exert effects outside the central nervous system to influence experimental allergic encephalomyelitis disease course</article-title>. <source/>J. Immunol.
<volume>171</volume>, <fpage>4385</fpage>–<lpage>4391</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.171.8.4385</pub-id><pub-id pub-id-type="pmid">14530364</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taracanova</surname><given-names>A.</given-names></name><name><surname>Alevizos</surname><given-names>M.</given-names></name><name><surname>Karagkouni</surname><given-names>A.</given-names></name><name><surname>Weng</surname><given-names>Z.</given-names></name><name><surname>Norwitz</surname><given-names>E.</given-names></name><name><surname>Conti</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>114</volume>, <fpage>E4002</fpage>–<lpage>E4009</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1524845114</pub-id><pub-id pub-id-type="pmid">28461492</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teeling</surname><given-names>J. L.</given-names></name><name><surname>Perry</surname><given-names>V. H.</given-names></name></person-group> (<year>2009</year>). <article-title>Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms</article-title>. <source/>Neuroscience
<volume>158</volume>, <fpage>1062</fpage>–<lpage>1073</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.07.031</pub-id><pub-id pub-id-type="pmid">18706982</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tete</surname><given-names>S.</given-names></name><name><surname>Tripodi</surname><given-names>D.</given-names></name><name><surname>Rosati</surname><given-names>M.</given-names></name><name><surname>Conti</surname><given-names>F.</given-names></name><name><surname>Maccauro</surname><given-names>G.</given-names></name><name><surname>Saggini</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Role of mast cells in innate and adaptive immunity</article-title>. <source/>J. Biol. Regul. Homeost. Agents
<volume>26</volume>, <fpage>193</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="pmid">22824746</pub-id></mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thangavel</surname><given-names>R.</given-names></name><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Zaheer</surname><given-names>S.</given-names></name><name><surname>Raikwar</surname><given-names>S.</given-names></name><name><surname>Ahmed</surname><given-names>M. E.</given-names></name><name><surname>Selvakumar</surname><given-names>G. P.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Glia maturation factor and mitochondrial uncoupling proteins 2 and 4 expression in the temporal cortex of Alzheimer’s disease brain</article-title>. <source/>Front. Aging Neurosci.
<volume>9</volume>:<fpage>150</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2017.00150</pub-id><pub-id pub-id-type="pmid">28572767</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thangavel</surname><given-names>R.</given-names></name><name><surname>Stolmeier</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Anantharam</surname><given-names>P.</given-names></name><name><surname>Zaheer</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Expression of glia maturation factor in neuropathological lesions of Alzheimer’s disease</article-title>. <source/>Neuropathol. Appl. Neurobiol.
<volume>38</volume>, <fpage>572</fpage>–<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2990.2011.01232.x</pub-id><pub-id pub-id-type="pmid">22035352</pub-id></mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theoharides</surname><given-names>T. C.</given-names></name><name><surname>Alysandratos</surname><given-names>K. D.</given-names></name><name><surname>Angelidou</surname><given-names>A.</given-names></name><name><surname>Delivanis</surname><given-names>D. A.</given-names></name><name><surname>Sismanopoulos</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Mast cells and inflammation</article-title>. <source/>Biochim. Biophys. Acta
<volume>1822</volume>, <fpage>21</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2010.12.014</pub-id><pub-id pub-id-type="pmid">21185371</pub-id></mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theoharides</surname><given-names>T. C.</given-names></name><name><surname>Asadi</surname><given-names>S.</given-names></name><name><surname>Patel</surname><given-names>A. B.</given-names></name></person-group> (<year>2013</year>). <article-title>Focal brain inflammation and autism</article-title>. <source/>J. Neuroinflammation
<volume>10</volume>:<fpage>46</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-10-46</pub-id><pub-id pub-id-type="pmid">23570274</pub-id></mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theoharides</surname><given-names>T. C.</given-names></name><name><surname>Donelan</surname><given-names>J. M.</given-names></name><name><surname>Papadopoulou</surname><given-names>N.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Conti</surname><given-names>P.</given-names></name></person-group> (<year>2004</year>). <article-title>Mast cells as targets of corticotropin-releasing factor and related peptides</article-title>. <source/>Trends Pharmacol. Sci.
<volume>25</volume>, <fpage>563</fpage>–<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2004.09.007</pub-id><pub-id pub-id-type="pmid">15491778</pub-id></mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theoharides</surname><given-names>T. C.</given-names></name><name><surname>Konstantinidou</surname><given-names>A. D.</given-names></name></person-group> (<year>2007</year>). <article-title>Corticotropin-releasing hormone and the blood-brain-barrier</article-title>. <source/>Front. Biosci.
<volume>12</volume>, <fpage>1615</fpage>–<lpage>1628</lpage>. <pub-id pub-id-type="doi">10.2741/2174</pub-id><pub-id pub-id-type="pmid">17127408</pub-id></mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theoharides</surname><given-names>T. C.</given-names></name><name><surname>Rozniecki</surname><given-names>J. J.</given-names></name><name><surname>Sahagian</surname><given-names>G.</given-names></name><name><surname>Jocobson</surname><given-names>S.</given-names></name><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Conti</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Impact of stress and mast cells on brain metastases</article-title>. <source/>J. Neuroimmunol.
<volume>205</volume>, <fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.09.014</pub-id><pub-id pub-id-type="pmid">18977036</pub-id></mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theoharides</surname><given-names>T. C.</given-names></name><name><surname>Stewart</surname><given-names>J. M.</given-names></name><name><surname>Panagiotidou</surname><given-names>S.</given-names></name><name><surname>Melamed</surname><given-names>I.</given-names></name></person-group> (<year>2016</year>). <article-title>Mast cells, brain inflammation and autism</article-title>. <source/>Eur. J. Pharmacol.
<volume>778</volume>, <fpage>96</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2015.03.086</pub-id><pub-id pub-id-type="pmid">25941080</pub-id></mixed-citation>
</ref>
<ref id="B193">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>E.</given-names></name><name><surname>Tran</surname><given-names>T. T.</given-names></name><name><surname>Vink</surname><given-names>R.</given-names></name></person-group> (<year>2010</year>). <article-title>A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death</article-title>. <source/>Neurosci. Lett.
<volume>481</volume>, <fpage>64</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2010.06.057</pub-id><pub-id pub-id-type="pmid">20599590</pub-id></mixed-citation>
</ref>
<ref id="B192">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>E.</given-names></name><name><surname>Vink</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson’s disease</article-title>. <source/>PLoS One
<volume>7</volume>:<fpage>e34138</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0034138</pub-id><pub-id pub-id-type="pmid">22485158</pub-id></mixed-citation>
</ref>
<ref id="B194">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tore</surname><given-names>F.</given-names></name><name><surname>Tuncel</surname><given-names>N.</given-names></name></person-group> (<year>2009</year>). <article-title>Mast cells: target and source of neuropeptides</article-title>. <source/>Curr. Pharm. Des.
<volume>15</volume>, <fpage>3433</fpage>–<lpage>3445</lpage>. <pub-id pub-id-type="doi">10.2174/138161209789105036</pub-id><pub-id pub-id-type="pmid">19860689</pub-id></mixed-citation>
</ref>
<ref id="B195">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tracey</surname><given-names>K. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Reflex control of immunity</article-title>. <source/>Nat. Rev. Immunol.
<volume>9</volume>, <fpage>418</fpage>–<lpage>428</lpage>. <pub-id pub-id-type="doi">10.1038/nri2566</pub-id><pub-id pub-id-type="pmid">19461672</pub-id></mixed-citation>
</ref>
<ref id="B196">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Träger</surname><given-names>U.</given-names></name><name><surname>Tabrizi</surname><given-names>S. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Peripheral inflammation in neurodegeneration</article-title>. <source/>J. Mol. Med. (Berl)
<volume>91</volume>, <fpage>673</fpage>–<lpage>681</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-013-1026-0</pub-id><pub-id pub-id-type="pmid">23546523</pub-id></mixed-citation>
</ref>
<ref id="B197">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tufekci</surname><given-names>K. U.</given-names></name><name><surname>Meuwissen</surname><given-names>R.</given-names></name><name><surname>Genc</surname><given-names>S.</given-names></name><name><surname>Genc</surname><given-names>K.</given-names></name></person-group> (<year>2012</year>). <article-title>Inflammation in Parkinson’s disease</article-title>. <source/>Adv. Protein Chem. Struct. Biol.
<volume>88</volume>, <fpage>69</fpage>–<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-398314-5.00004-0</pub-id><pub-id pub-id-type="pmid">22814707</pub-id></mixed-citation>
</ref>
<ref id="B198">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utsuyama</surname><given-names>M.</given-names></name><name><surname>Shiraishi</surname><given-names>J.</given-names></name><name><surname>Takahashi</surname><given-names>H.</given-names></name><name><surname>Kasai</surname><given-names>M.</given-names></name><name><surname>Hirokawa</surname><given-names>K.</given-names></name></person-group> (<year>2003</year>). <article-title>Glia maturation factor produced by thymic epithelial cells plays a role in T cell differentiation in the thymic microenvironment</article-title>. <source/>Int Immunol
<volume>15</volume>, <fpage>557</fpage>–<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1093/intimm/dxg056</pub-id><pub-id pub-id-type="pmid">12697657</pub-id></mixed-citation>
</ref>
<ref id="B200">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villarán</surname><given-names>R. F.</given-names></name><name><surname>Espinosa-Oliva</surname><given-names>A. M.</given-names></name><name><surname>Sarmiento</surname><given-names>M.</given-names></name><name><surname>De Pablos</surname><given-names>R. M.</given-names></name><name><surname>Arguelles</surname><given-names>S.</given-names></name><name><surname>Delgado-Cortés</surname><given-names>M. J.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson’s disease</article-title>. <source/>J. Neurochem.
<volume>114</volume>, <fpage>1687</fpage>–<lpage>1700</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06879.x</pub-id><pub-id pub-id-type="pmid">20584104</pub-id></mixed-citation>
</ref>
<ref id="B201">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visan</surname><given-names>I.</given-names></name></person-group> (<year>2017</year>). <article-title>Neuroimmune interactions: astrocytes</article-title>. <source/>Nat. Immunol.
<volume>18</volume>:<fpage>254</fpage>. <pub-id pub-id-type="doi">10.1038/ni.3700</pub-id><pub-id pub-id-type="pmid">28198833</pub-id></mixed-citation>
</ref>
<ref id="B202">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Chu</surname><given-names>C. H.</given-names></name><name><surname>Qian</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>S. H.</given-names></name><name><surname>Wilson</surname><given-names>B.</given-names></name><name><surname>Oyarzabal</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidase</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>12490</fpage>–<lpage>12503</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.2238-14.2014</pub-id><pub-id pub-id-type="pmid">25209287</pub-id></mixed-citation>
</ref>
<ref id="B203">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Oyarzabal</surname><given-names>E.</given-names></name><name><surname>Wilson</surname><given-names>B.</given-names></name><name><surname>Qian</surname><given-names>L.</given-names></name><name><surname>Hong</surname><given-names>J. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Substance P enhances microglial density in the substantia nigra through neurokinin-1 receptor/NADPH oxidase-mediated chemotaxis in mice</article-title>. <source/>Clin. Sci.
<volume>129</volume>, <fpage>757</fpage>–<lpage>767</lpage>. <pub-id pub-id-type="doi">10.1042/cs20150008</pub-id><pub-id pub-id-type="pmid">26223840</pub-id></mixed-citation>
</ref>
<ref id="B204">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Xiong</surname><given-names>J. Q.</given-names></name><name><surname>Ren</surname><given-names>X. B.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name></person-group> (<year>2012</year>). <article-title>The role of Nogo-A in neuroregeneration: a review</article-title>. <source/>Brain Res. Bull.
<volume>87</volume>, <fpage>499</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresbull.2012.02.011</pub-id><pub-id pub-id-type="pmid">22414960</pub-id></mixed-citation>
</ref>
<ref id="B205">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname><given-names>M.</given-names></name><name><surname>Silver</surname><given-names>R.</given-names></name><name><surname>Silverman</surname><given-names>A. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Central nervous system neurons acquire mast cell products via transgranulation</article-title>. <source/>Eur. J. Neurosci.
<volume>22</volume>, <fpage>2238</fpage>–<lpage>2248</lpage>. <pub-id pub-id-type="doi">10.1111/j.1460-9568.2005.04429.x</pub-id><pub-id pub-id-type="pmid">16262662</pub-id></mixed-citation>
</ref>
<ref id="B206">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>B.</given-names></name></person-group> (<year>2009</year>). <article-title>Superoxide anion regulates the mitochondrial free Ca<sup>2+</sup> through uncoupling proteins</article-title>. <source/>Antioxid. Redox Signal.
<volume>11</volume>, <fpage>1805</fpage>–<lpage>1818</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2009.2427</pub-id><pub-id pub-id-type="pmid">19361273</pub-id></mixed-citation>
</ref>
<ref id="B207">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>B.</given-names></name></person-group> (<year>2010</year>). <article-title>Superoxide anion, uncoupling proteins and Alzheimer’s disease</article-title>. <source/>J. Clin. Biochem. Nutr.
<volume>46</volume>, <fpage>187</fpage>–<lpage>194</lpage>. <pub-id pub-id-type="doi">10.3164/jcbn.09-104-2</pub-id><pub-id pub-id-type="pmid">20490313</pub-id></mixed-citation>
</ref>
<ref id="B208">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yehya</surname><given-names>M.</given-names></name><name><surname>Torbey</surname><given-names>M. T.</given-names></name></person-group> (<year>2017</year>). <article-title>The role of mast cells in intracerebral hemorrhage</article-title>. <source/>Neurocrit. Care [Epub ahead of print]. <pub-id pub-id-type="doi">10.1007/s12028-017-0416-5</pub-id><pub-id pub-id-type="pmid">28620846</pub-id></mixed-citation>
</ref>
<ref id="B209">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaheer</surname><given-names>A.</given-names></name><name><surname>Fink</surname><given-names>B. D.</given-names></name><name><surname>Lim</surname><given-names>R.</given-names></name></person-group> (<year>1993</year>). <article-title>Expression of glia maturation factor β mRNA and protein in rat organs and cells</article-title>. <source/>J. Neurochem.
<volume>60</volume>, <fpage>914</fpage>–<lpage>920</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.1993.tb03237.x</pub-id><pub-id pub-id-type="pmid">8436977</pub-id></mixed-citation>
</ref>
<ref id="B210">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaheer</surname><given-names>A.</given-names></name><name><surname>Knight</surname><given-names>S.</given-names></name><name><surname>Zaheer</surname><given-names>A.</given-names></name><name><surname>Ahrens</surname><given-names>M.</given-names></name><name><surname>Sahu</surname><given-names>S. K.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name></person-group> (<year>2008a</year>). <article-title>Glia maturation factor overexpression in neuroblastoma cells activates glycogen synthase kinase-3β and caspase-3</article-title>. <source/>Brain Res.
<volume>1190</volume>, <fpage>206</fpage>–<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2007.11.011</pub-id><pub-id pub-id-type="pmid">18054898</pub-id></mixed-citation>
</ref>
<ref id="B213">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaheer</surname><given-names>A.</given-names></name><name><surname>Zaheer</surname><given-names>S.</given-names></name><name><surname>Thangavel</surname><given-names>R.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Sahu</surname><given-names>S. K.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name></person-group> (<year>2008b</year>). <article-title>Glia maturation factor modulates β-amyloid-induced glial activation, inflammatory cytokine/chemokine production and neuronal damage</article-title>. <source/>Brain Res.
<volume>1208</volume>, <fpage>192</fpage>–<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2008.02.093</pub-id><pub-id pub-id-type="pmid">18395194</pub-id></mixed-citation>
</ref>
<ref id="B214">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaheer</surname><given-names>S.</given-names></name><name><surname>Thangavel</surname><given-names>R.</given-names></name><name><surname>Sahu</surname><given-names>S. K.</given-names></name><name><surname>Zaheer</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>Augmented expression of glia maturation factor in Alzheimer’s disease</article-title>. <source/>Neuroscience
<volume>194</volume>, <fpage>227</fpage>–<lpage>233</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.07.069</pub-id><pub-id pub-id-type="pmid">21835226</pub-id></mixed-citation>
</ref>
<ref id="B211">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaheer</surname><given-names>A.</given-names></name><name><surname>Yorek</surname><given-names>M. A.</given-names></name><name><surname>Lim</surname><given-names>R.</given-names></name></person-group> (<year>2001</year>). <article-title>Effects of glia maturation factor overexpression in primary astrocytes on MAP kinase activation, transcription factor activation and neurotrophin secretion</article-title>. <source/>Neurochem. Res.
<volume>26</volume>, <fpage>1293</fpage>–<lpage>1299</lpage>. <pub-id pub-id-type="pmid">11885780</pub-id></mixed-citation>
</ref>
<ref id="B212">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaheer</surname><given-names>A.</given-names></name><name><surname>Zaheer</surname><given-names>S.</given-names></name><name><surname>Sahu</surname><given-names>S. K.</given-names></name><name><surname>Knight</surname><given-names>S.</given-names></name><name><surname>Khosravi</surname><given-names>H.</given-names></name><name><surname>Mathur</surname><given-names>S. N.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>A novel role of glia maturation factor: induction of granulocyte-macrophage colony-stimulating factor and pro-inflammatory cytokines</article-title>. <source/>J. Neurochem.
<volume>101</volume>, <fpage>364</fpage>–<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04385.x</pub-id><pub-id pub-id-type="pmid">17250654</pub-id></mixed-citation>
</ref>
<ref id="B215">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Dong</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Cerebral mast cells contribute to postoperative cognitive dysfunction by promoting blood brain barrier disruption</article-title>. <source/>Behav. Brain Res.
<volume>298</volume>, <fpage>158</fpage>–<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2015.11.003</pub-id><pub-id pub-id-type="pmid">26554724</pub-id></mixed-citation>
</ref>
<ref id="B216">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zeng</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>G.</given-names></name><name><surname>He</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Mast cell tryptase induces microglia activation via protease-activated receptor 2 signaling</article-title>. <source/>Cell. Physiol. Biochem.
<volume>29</volume>, <fpage>931</fpage>–<lpage>940</lpage>. <pub-id pub-id-type="doi">10.1159/000171029</pub-id><pub-id pub-id-type="pmid">22613992</pub-id></mixed-citation>
</ref>
<ref id="B217">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Du</surname><given-names>R. H.</given-names></name><name><surname>Qiao</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>C. Y.</given-names></name><name><surname>Zhang</surname><given-names>K. Z.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease</article-title>. <source/>Mol. Neurodegener.
<volume>11</volume>:<fpage>28</fpage>. <pub-id pub-id-type="doi">10.1186/s13024-016-0094-3</pub-id><pub-id pub-id-type="pmid">27084336</pub-id></mixed-citation>
</ref>
<ref id="B218">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Qu</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Activation of microglia by histamine and substance P</article-title>. <source/>Cell. Physiol. Biochem.
<volume>34</volume>, <fpage>768</fpage>–<lpage>780</lpage>. <pub-id pub-id-type="doi">10.1159/000363041</pub-id><pub-id pub-id-type="pmid">25170632</pub-id></mixed-citation>
</ref>
<ref id="B219">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>K.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Tang</surname><given-names>G.</given-names></name><name><surname>Zheng</surname><given-names>B.</given-names></name><name><surname>Zheng</surname><given-names>Z.</given-names></name></person-group> (<year>2013</year>). <article-title>A case of early onset Parkinson’s disease after major stress</article-title>. <source/>Neuropsychiatr. Dis. Treat.
<volume>9</volume>, <fpage>1067</fpage>–<lpage>1069</lpage>. <pub-id pub-id-type="doi">10.2147/ndt.s48455</pub-id><pub-id pub-id-type="pmid">23950648</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>